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ABSTRACT

The purpose of the study was to assess the accuracy, validity and time-savings of
automated atlas-based segmentations (AABS). Further, the study assessed the inter- and intra
observer variability in the delineation of the prostate bed (PB) and the five regions of interest for
postoperative conformal radiotherapy in prostate cancer patients. Finally, the study reports on the
development of an appropriate methodology for similar studies. Seventy-five DICOM Computed
Tomography (CT) datasets were obtained to create the prostate bed atlas and another five
datasets were retrospectively contoured by the atlas builder, the expert panel and the AABS tool.
Consensus segmentations (CS) were also generated. The mean dice similarity coefficient
comparing the edited AABS and CS was 0.67, 0.88, 0.93, 0.92, 0.54 and 0.78 for the PB,
bladder, left- and right femoral head, penile bulb and rectum, respectively. Significant inter
observer variation was observed in the PB and bilateral femoral heads. Significant time savings
were obtained using the average AABS editing time (p = 0.003) versus the manual contouring
time. We successfully developed a methodology and validated the AABS tool for routine clinical
use.

Keywords: atlas-based segmentations, automated contours, computer-assisted segmentations,
methodology, technology assessment, validation, prostate cancer, prostate bed, prostatic fossa,
inter-observer variability, intra-observer variability
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1.0 Introduction
Prostate cancer continues to be the most prominent cancer among males in Canada. The
disease burden from the adenocarcinoma of the prostate has had a considerable impact on patient
health and on the entire health care system. It is among the top three causes of cancer-related
death and the most diagnosed malignant neoplasm among males in Canada (Canadian Cancer
Society, 2011). Several biomarkers and diagnostic tests are performed to gauge the stage and
progression of the cancer. Once all the necessary clinical information about the disease is
collected, patients are stratified as low-, medium- or high-risk patients according to the current
status of the disease and the risk of disease progression. The radical prostatectomy procedure
(surgical removal of the prostate) is one of the curative treatment options for patients with
clinically localized prostate cancer. Thirty-five to fifty percent of patients that underwent the
procedure experienced a biochemical recurrence (Partin and Oesterling, 1994). The 15-year
prostate cancer-specific mortality rate for post-prostatectomy patients that had a biochemical
recurrence was 36% and those that did not experience a biochemical recurrence was 0% (Uchio
et al, 2010). This highlights the importance of treating patients at a higher risk of future disease
progression.
Three randomized controlled trials have demonstrated the therapeutic benefits of adjuvant
radiotherapy over active surveillance following radical prostatectomy in patients at high risk of
recurrence after surgery (involved resection margins or pathologic T3 cancer) (Bolla et al, 2005;
Thompson et al, 2009; Wiegel et al, 2009). Adjuvant radiotherapy demonstrated a significant
reduction in biochemical recurrence at 5 years (Bolla et al, 2005; Wiegel et al, 2009), clinical
progression and local failure (Bolla et al, 2005). Thompson and colleagues (2009) found that
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adjuvant radiotherapy was significantly associated with prolonging metastatic-free survival and
overall survival.
All three trials ostensibly irradiated the same region, the prostatic fossa, yet the definition
of the prostatic fossa continues to be debated. Previous studies have shown the presence of inter
observer variability among experts in the delineation of the prostatic fossa (Symon et al, 2011;
Wiltshire et al, 2007). There has been little consensus as to what embodies an appropriate
clinical target volume (CTV) for radiotherapy to this area. Several clinical guidelines have been
published proposing a definition for the delineation of the CTV in postoperative prostate cancer
patients to reduce the inter-observer variability, but the guidelines themselves are still subject to
inter-observer variability in both interpretation and execution. Another potential solution to the
variability challenges is the use of automatic segmentation tools, specifically a technology called
atlas-based segmentation.
Atlas-based segmentation is a computer-assisted tool used in the treatment planning stage
for radiotherapy patients. This medical technology utilizes an algorithm that resamples local data
to automatically outline the structures of interest to be irradiated. The algorithm has been shown
to achieve consistency in the delineation of anatomical regions (Piper, 2007), but the accuracy
and validity of these automated segmentations need to be assessed and proven. The present paper
develops and proposes a methodological approach to evaluate the accuracy, validity and
potential time-savings of an atlas-based segmentation tool and to assess inter- and intra observer
variability in the delineation of the post-prostatectomy CTV (prostatic fossa) and the regions of
interest (ROI).

3

2.0 Literature Review

2.1 Prostate Cancer

Prostate cancer is the most common cancer observed in males and the third most common
cancer-related death behind lung cancer and colorectal cancer. In 2011, the Canadian Cancer
Society estimated 25,500 new cases of prostate cancer will be diagnosed in Canada and 4,100
will die from it. This accounts for the largest proportion of cancer cases for Canadian males and
the third largest proportion of estimated deaths (Canadian Cancer Society, 2011). These are not
isolated findings. An estimated 217,730 new cases of prostate cancer will be diagnosed,
accounting for about 28% of all cancers for American males. An estimated 32,050 American
males will die from this form of cancer, accounting for 11% of all cancer-related deaths, second
to only lung cancer (Jemal et al, 2010).

2.1.1 Diagnostic Workup of Prostate Cancer

The diagnostic staging and treatment of prostate cancer requires several clinical
evaluations, diagnostic tests, a complete history, a physical examination that includes a digital
rectal examination (referred to as DRE), a prostate-specific antigen (referred to as PSA) test, a
transrectal ultrasound (TRUS)-guided sextant biopsies and other radiological scans. PSA is a
biomarker unique to both the prostate tissue and prostate cancer. There are several types of PSA
testing for the screening of prostate cancer. A total PSA range of 0-4 ng/ml is considered normal,
although considerable variability according to age and gland volume renders a single PSA cutoff

as imperfect for cancer detection. Despite this, PSA measurements and the DRE are the most
commonly used modalities used to diagnosis and stage prostate cancer.
Clinically localized prostate cancer presents as an induration (hardening of soft tissue) or
nodularity (presence of nodules) of the prostate on DRE during a physical examination.
Examinations of the extracapsular space and seminal vesicles on the DRE provide evidence for
the staging of the cancer and the detection of extraprostatic extension. Further, the examination
of the lymph node-bearing areas and the bone can provide information on the stage of the cancer.
The TRUS-guided biopsy is the current standard to confirm a cancer diagnosis in patients with
suspected prostate cancer and to estimate the tumor grade. Bone scans are used if patients are at a
higher disease stage or are experiencing bone pain to determine if there is metastatic spread to
the bony anatomy. Computed Tomography (CT) scans of the abdomen and pelvis are used to
rule out lymph node metastasis in high-risk individuals (Kantoff and Taplin, 2010).

2.1.2 Staging of Prostate Cancer

In 1977, the American Joint Committee on Cancer (AJCC) published the first edition of
their cancer staging manual for clinical use which was not adopted by the International Union
Against Cancer until 1997. It is known as the TNM Staging System that describes the extent of
the tumor (T), the extent of the spread to lymph nodes (N), and the presence of metastasis (M).
The TNM Staging System has gone through a 7th revision which was adopted in 2010 (Edge et
al, 2010).
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2.1.3 Assessment of Disease Risk

In the preoperative context, risk stratification schemas categorize patients based on
clinicopathologic parameters to help determine the risk of disease progression and the best
treatment course for the patient. There are several risk stratification schemas for prostate cancer.
D’Amico and colleagues (1998) created a risk stratification system for prostate cancer patients to
predict the risk of disease progression, compare treatment results and to provide insight on the
appropriate treatment course. Lukka and colleagues (2001) developed a Canadian consensus
guideline that defined low-, intermediate-, and high-risk disease to allow for appropriate
treatment and disease management decisions.
1. Low-risk - must have all of the following:
• PSA < 10 ng/mL
• Gleason < 6
• Stage T2a or less
2. Intermediate-risk - must have all of the following if not in low-risk category:
• PSA < 20 ng/ml
• Gleason < 8
• Stage T1 or T2
3. High-risk - must have any of the following:
• PSA > 20 ng/mL
• Gleason > 8
Stage T3a or greater

6
Generally speaking those patients with low or intermediate risk disease are treated with
local therapies like radiotherapy or surgery; those patients with high risk disease are generally
treated with a combination of therapies such as surgery and radiation or radiation plus hormonal
therapy.

2.1.4 Treatment of Prostate Cancer: Radical Prostatectomy

An estimated 92% of the new prostate cancer cases will be diagnosed at local or regional
stages of disease (Jemal et al, 2010). Radical prostatectomy is a well established curative
treatment option for clinically localized prostate carcinomas based upon rates of long-term
cancer control, morbidity and mortality rates and side effects profde. The procedure has been
shown to reduce the risk of death in patients with local or regional stages of prostate cancer
(Uchio et al, 2010; Bill-Axelson et al, 2008; Underwood et al, 2005; Zincke et al, 1994). Patients
that underwent the procedure demonstrated a reduction in disease specific mortality, overall
mortality and the risk of disease progression (local and metastatic) compared to watchful waiting
(Bill-Axelson et al, 2008; Wong et al, 2006).
The American Urological Association considers radical prostatectomy as an appropriate
treatment option for patients with low- and intermediate-risk prostate cancer (Thompson et al,
2007). For patients with clinical T3 prostate cancer, radical prostatectomy with adjuvant
radiotherapy is one standard approach for men with an adequate life expectancy and without
serious comorbidity (Klein, 2010).

2.1.5 Prostate Cancer Recurrence
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Partin and Oesterling (1994) observed that 35% to 50% of patients that underwent a
radical prostatectomy developed biochemical recurrence and up to half of these patients
experienced clinically identified local recurrence and the remainder had distant failure alone or
had a combination of local and distant failure. Other studies reported similar proportions of
patients having local failure, 53.5% (Connolly et al, 1996) and 41% (Leventis et al, 2001). The
15-year prostate cancer-specific mortality rate after prostatectomy of those that experienced local
recurrence (via biochemical recurrence) was 36% and those that did not experience local
recurrence was 0% (Uchio et al, 2010). Therefore it is important to identify the role of adjuvant
therapies in post-prostatectomy patients in order to reduce the risk of prostate cancer morbidity
and mortality due to recurrence after surgery.

2.2 Indications for Postoperative Treatment

Adverse risk features in post-prostatectomy patients includes extracapsular extension
(pathological extension of the disease beyond the prostate), positive surgical margins and
invasion of one or both seminal vesicles. Adverse risk features increase the risk of recurrence,
cancer progression and death (Stephenson et al, 2005; Epstein et al, 1993). Positive surgical
margins and extracapsular extension are associated with an increased risk of PSA recurrence and
local recurrence (Han et al, 2001; Hull et al, 2002). In a study looking at 15-year prostate cancerspecific mortality, seminal vesicle invasion (p <0.001), secondary Gleason grade 4-5 (each with
p <0.001) and surgery year (p <0.002) were significant predictors of prostate cancer-specific
mortality (Eggener et al, 2011). Postoperative prostate cancer patients possessing any of these
three indicators are at a higher risk for disease progression and mortality.
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2.3 Radiotherapy

The relationship between tumor control and clinically significant toxicities of normal
tissues is referred to as the therapeutic ratio. It is the general intention for any acute or long-term
treatment options to maximize the tumor control while limiting toxicities to normal tissues. The
concept of the therapeutic ratio is essential in determining the patient’s acceptable balance
between the cure/control versus the treatment side-effects.
The goal of radiotherapy is to sufficiently separate the dose-response curves of local
tumor control and normal tissue complications. A dose-response curve is a graphical
representation of the effect caused by the radiation treatment plotted against the radiation
treatment dose to illustrate the relationship of the treatment effects to the changes in the dose.
Radiotherapy is a local therapeutic option that can be used alone or in combination with other
treatment modalities. Roach and colleagues conducted a retrospective study (2000) and a
prospective study (1999) that suggested the long-term efficacy of radiotherapy in the
management of localized prostate cancer. The prospective study suggested that compared no
initial treatment, radiotherapy was associated with a higher likelihood of surviving prostate
cancer at ten years (Roach et al, 1999). The retrospective study found similar results that
suggested radiotherapy was associated with improved survival among patients with poorly
differentiated tumors (Roach et al, 2000). While no randomized controlled trials of external
beam radiotherapy and surgery exist, comparison of outcomes among similar risk strata suggest
comparable disease control and quality of life among men treated with either modality (Klein et
al, 2003; Klein et al, 2009; Kupelian et al, 2004).
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2.3.1 Three-Dimensional Conformal Radiotherapy and Intensity
Modulated Radiotherapy

External-beam radiotherapy for prostate cancer has evolved to allow radiation oncologists
to improve the therapeutic ratio by simultaneously increasing the dose to the tumor area while
lowering the exposure to the surrounding normal tissues. The three-dimensional conformal
radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) have greatly improved the
ability to treat cancers all over the body and reduce complications to normal tissues.
The use of 3D-CRT and IMRT permits greater versatility in shaping radiation treatment
volume to better conform to the tumor volume. Conventional radiotherapy targets the patient’s
tumor from a few beam directions (as the accelerator rotates about the patient) aimed at a single
point called the isocenter that geometrically represents the center of treatment volume (generally
centered on the tumor containing region). The American College of Radiology’s committee on
Appropriateness Criteria and its expert panel developed criteria for external beam radiotherapy
treatment planning for clinically localized prostate cancer (Roach et al, 2000). The criteria guide
physicians in the determination of the appropriate imaging examinations for the diagnosis and
treatment of prostate cancer. The committee and expert panel reviewed the literature and
assigned an appropriateness rating for each prostate cancer subtopic under review based on their
interpretations of the available evidence. Within the literature search compiled by the panel, they
noted that the treatment of prostate cancer with conventional external-beam radiotherapy using
older, non-conformal techniques were associated with inadequate coverage of the target volume
in at least 20% to 41% of the patients treated (Roach et al, 2000).
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3D-CRT and IMRT planning and delivery utilizes pretreatment cross-sectional imaging,
such as computed tomography (CT Simulation), to determine the location and three-dimensional
shape of the target to be treated. In the treatment of prostate cancer, 3D-CRT and IMRT allows
the radiation oncologist to more precisely conform the delivered radiation dose to the prostate
while avoiding surrounding normal tissues when compared to non-conformal radiation
techniques. It has been demonstrated that 3D-CRT and IMRT improves radiation treatment
planning and delivery and can subsequently allow an increase in the radiotherapy dose to
improve tumor control without dramatically increasing side effects in surrounding normal tissues
(Pollack et al, 2002; Zietman et al, 2005; Zelefsky et al, 2008). Though both technologies can
create more sophisticated treatment plans, IMRT goes one step beyond 3D-CRT by permitting
variations in the radiation intensity as well as shape within each beam (Hoppe at el, 2010). These
variations allow for considerably greater flexibility in the distribution of doses within the
treatment volume.
The initial and final steps of the treatment planning process are similar for both the 3DCRT and IMRT, but they differ in several intermediate steps of the treatment planning process.
The two treatment technologies have identical patient imaging and simulation, but differ in a
number of important plan optimization steps (Hoppe et al, 2010). Simulation and segmentation
of the target and/or organ are widely adopted standards of practice designed to delineate the
treatment targets and nearby critical structures and construct any necessary immobilization or
treatment devices. Once all the relevant tissues have been delineated, the radiation oncologist
specifies the desired dose to the tumor volumes and minimizes the dose to normal tissues. In the
3D-CRT treatment modality (slightly older than IMRT), a medical physicist or dosimetrist
manually manipulates the radiation beams, volume shapes, and beam intensities to best satisfy
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the desired treatment dose criteria, and a computer calculates the dose distribution. IMRT usually
involves a computerized iteration of radiation beams and can apply different dose intensities
within each radiation beam that results in a significantly enhanced dose distribution (Xing et al,
2005). The maturation of the IMRT technology has demonstrated the advantages of IMRT over
3D-CRT in dosimetry (calculation of the absorbed dose in the tissues of interest from the
exposure of radiation), especially for prostate cancer (Xia et al, 2001; Burman et al, 1997; Ling
et al, 1996). Zelefsky and colleagues (2000) reported that the use of dose escalation by IMRT
improved tumor control and reduced normal tissues exposure when compared to 3D-CRT.
The advantages of 3D-CRT over conventional external-beam radiotherapy in the
management of prostate cancer and simultaneously reducing late complications and exposure to
normal tissues have been demonstrated in a number of studies (Michalski et al, 2002; Ryu et al,
2002). These advantages are multiplied with the use of IMRT. Zelefsky and colleagues (2002
and 2008) illustrated the reduction in toxicity to normal tissues when comparing IMRT to 3DCRT. They found high radiation doses through the delivery of IMRT was associated with
improved tumor control and decreased the risk of distant metastases (Zelefsky et al, 2008).
Within the context of radiotherapy in Ontario, a recent summary of the evidence of IMRT
supports the use of this technique in the treatment of prostate cancer and suggests guidelines for
treating prostate cancer with radiation (Bauman et al, 2010).

2.4 Adjuvant Radiotherapy vs. Salvage Radiotherapy

Given the risk of recurrence in patients with adverse risk factors after radical
prostatectomy, the use of radiotherapy as an adjunct to surgery has been explored. Adjuvant

12

radiotherapy (ART) is a therapeutic option that radiates the prostatic fossa in the immediate
postoperative period. It is a local intervention that aims to control the residual tumor cells in the
prostatic fossa following surgery in order to limit the risk of biochemical or local recurrences.
The prostatic fossa is the region in the pelvis that the prostate once occupied prior to its surgical
removal. ART is a treatment option that has been gaining in popularity as the strategy to
eradicate residual local disease and to control the tumor in high-risk patients. However, there is a
downside to this treatment option. ART can potentially lead to an overtreatment of patients that
do not need radiotherapy, that is, patients that have already been cured.
Salvage radiotherapy is an alternative treatment option for postoperative prostate cancer
patients that were actively monitored. Once a biochemical recurrence has been confirmed, the
patient may undergo radiation treatment at that time. Several retrospective studies have
demonstrated the treatment’s ability to control disease recurrence. One study at the Mayo Clinic
found the five-year biochemical recurrence-free survival rate for salvage radiotherapy patients
was 63% (Ward et al, 2005). Another retrospective study found the five-year biochemical
recurrence-free survival rate was 54% for salvage radiotherapy patients (Paparei et al, 2009). No
randomized controlled trial has been conducted to explore the therapeutic benefits of salvage
radiotherapy over observational strategies for post-prostatectomy prostate cancer patients. The
optimal therapeutic intervention for postoperative prostate cancer patients (immediate adjuvant
therapy for patients with adverse risk features versus salvage radiotherapy at the first signs of
PSA recurrence) continues to be investigated. The RADICALS-RT trial is currently accruing
participants and was created to resolve this dilemma by randomly assigning participants to the
early radiotherapy (ART) arm or to the deferred radiotherapy (early salvage radiotherapy) arm
(Parker et al, 2010).
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A growing body of literature supports the use of ART. A multi-institutional, matched
case-control (to pT3-4N0 prostate cancer), retrospective study that analyzed 211 patients
receiving ART and 238 patients receiving salvage radiotherapy suggested the use of ART over
salvage radiotherapy in the management of prostate cancer after radical prostatectomy. They
found that ART significantly reduces the risk of long-term biochemical progression compared
with salvage radiotherapy (Trabulsi et al, 2008).

2.4.1 Adjuvant Radiotherapy

Since 2005, three randomized trials have been published evaluating ART after radical
prostatectomy. Thompson and colleagues (2009) conducted a multi-center controlled trial on 425
men with pT3 N0M0 prostate cancer and randomized them to 60 to 64 Gy dose of adjuvant
radiotherapy or to the wait-and-see arm. Their primary endpoint was metastasis-free survival.
Radiotherapy was given in 30 to 32 fractions to the prostatic fossa and paraprostatic tissues
(tissues surrounding the prostatic fossa region). They found a significant difference in patients
that experienced metastatic disease or death in those that were randomized to the ART arm
(43%) compared to the observation arm (54%). For their primary outcome of metastatic-free
survival, ART had a hazard ratio of 0.71 (95% Cl (0.54, 0.94); p value = 0.016) compared to
observation, indicating that ART was associated with better metastatic-free survival than
observation. There was also a significant improvement in overall survival between ART and
observation, 41% in the ART arm and 52% in the observation arm died with a hazard ratio of
0.72 (95% Cl (0.55, 0.96); p value = 0.023) (Thompson et al, 2009). Moinpour and colleagues
(2008) compared the short- and long-term effects of ART on health-related quality of life on the
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same patient population as the Thompson et al (2009) trial. They reported that patients given
ART had worse short-term bowel function, but showed little difference in bowel function after
two years. Urinary function and quality of life was shown to be worse in the ART group. Erectile
dysfunction was similar across both groups (Moinpour et al, 2008).
Bolla and colleagues (2005) also conducted a randomized multi-centered controlled trial
on 1005 patients with pT2-3 NO, no metastases and at least one risk factor (tumor growth beyond
the capsule, positive surgical margins, or invasion of the seminal vesicles). The patients were
randomized to either the ART arm or the observation arm until local failure. The irradiation
group was given a dose of 50 Gy over 25 fractions to a volume that included the surgical limits
from the seminal vesicles to the prostatic apex. An additional dose of 10 Gy over a week was
given to a reduced volume from the previous landmarks. The primary endpoint of the clinical
trial was biochemical progression-free survival. The authors found statistically significant
improvements in five-year biochemical progression-free survival in the individuals randomized
to ART group compared to the observation group, 74% versus 52.6% respectively, with a hazard
ratio = 0.48 (98% Cl (0.37, 0.62); p value <0.0001). The five-year cumulative incidence of
biochemical failure was 21.4% and 44.2% for the ART and observation arms respectively. The
ART arm had significantly higher clinical progression-free survival and a longer time to
biochemical failure than the observation arm (Bolla et al, 2005). At five years, there was no
significant difference between the two groups in overall survival.
Wiegel and colleagues (2009) conducted a randomized multi-centered controlled trial on
388 patients that had no known distant metastases and were pT3-4 pNO with positive or negative
surgical margins. A dose of 60 Gy was given in 30 fractions to the volume that included the
surgical limits from the seminal vesicles to the apex with a 1-cm security margin to include any
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subclinical disease in the periprostatic area. Their primary endpoint was progression-free
survival defined as either biochemical progression, local or distant clinical recurrence, or death
for any reason. The five-year biochemical progression-free survival comparing the ART group
and the observation group was significantly different at 72% and 54% respectively and hazard
ratio = 0.53 (95% Cl (0.37, 0.79); p value = 0.001). There was a significant difference in late
toxicity in the bladder and rectum that indicated a significantly larger amount of patients in the
ART group had late toxicity compared to the control group (Wiegel et al, 2009).
All three randomized controlled trials suggest that ART is a superior treatment option to
the observation alternative for post-operative locally advanced prostate cancer patients. There
does seem to be an increase in late toxicity incidences in the ART patients when compared to the
control group (Moinpour et al, 2008; Wiegel et al, 2009). The differences seen in the short- and
long-term toxicity effects from the three trials may be explained by the time frames in which
these studies were conducted (availability of PSA for stratifying patients for treatment) and
duration of follow-up and differences in salvage therapies utilized in the observation arm among
the three trials. Also there were differences in the radiotherapy technology and techniques
implemented by each of the trials and differences in outcomes reported may reflect variability in
these technical variables, particularly, variability in the delineation of the irradiated volume.

2.5 Consensus Guidelines for Contouring the Prostate Bed

The International Commission for Radiation Units (ICRU) has been promoting the use of
common terminology to describe the tumor volumes (ICRU, 1993). They define the gross tumor
volume (GTV) as any disease that can be identified through imaging modalities or a physical
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examination. For prostate radiotherapy the entire gland is often considered the GTV for radiation
therapy planning purposes. The clinical target volume (CTV) encompasses the GTV with a
margin that includes the presumed microscopic extension of the disease or subclinical nodal
involvement. The CTV may expand past the GTV to include adjacent organs or regions of cancer
spread. In the postoperative setting, there is no GTV present and the “prostate bed” (remaining
tissues surrounding the prostate gland “in-vivo”) represents the CTV. To appropriately treat the
tumor volume, the CTV must be determined. Under-representation of the CTV leaves residual
“at risk” tissue volumes untreated, while an over-represented CTV leads to an increased risk of
toxicity effects to normal tissues.
Definitions for the clinical target volumes and organs at risk have been available since
1993 (ICRU, 1993), yet there still appears to be variation in volume delineation within the
radiotherapy community. A clear definition for the CTV is required to facilitate a standard of
practice within and across institutions. In the era of 3D-CRT and IMRT these definitions provide
guidance as to the optimum contouring (delineation of the boundaries of targets and normal
tissues) on cross sectional imaging for radiotherapy planning. Recently, a number of
radiotherapy working groups have attempted to provide definitions of an appropriate CTV for
postoperative prostate cancer patients.
Since 2007, five proposed guidelines for the contouring of the prostate bed have been
published (Michalski et al, 2010; Sidhom et al, 2008; Miralbell et al, 2007; Poortmans et al,
2007; Wiltshire et al, 2007). All five guidelines proposed a minimum volume to be irradiated in a
typical postoperative scenario and took similar approaches in the development of the guidelines.
Each group of investigators conducted a literature review to identify the patterns of failure and
its location (Michalski et al, 2010; Sidhom et al, 2008; Miralbell et al, 2007; Poortmans et al,
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2007; Wiltshire et al, 2007). Most held consensus conferences and formed working groups to
finalize the guidelines (Michalski et al, 2010; Sidhom et al, 2008; Poortmans et al, 2007;
Wiltshire et al, 2007). There are also similarities to the proposed CTV, for example Poortmans et
al (2007) and Miralbell et al (2007) suggested omitting the retrovesicle space.
The similarities end there, in that key differences in the various methodologies
predictably led to contrasting CTV guidelines. For example, the Radiation Therapy Oncology
Group (RTOG) consensus guideline was developed by genitourinary radiation oncologists
(physicians specializing in the radiation treatment of prostate cancer) (Michalski et al, 2010),
while the other studies took an interdisciplinary approach and included urologists and
radiologists (Sidhom et al, 2008; Miralbell et al, 2007; Wiltshire et al, 2007). Wiltshire et al
(2007) and Michalski et al (2010) differed in the data distribution method and the mathematical
modeling for the generation of their initial consensus CTV. The RTOG group separated itself
from the other groups by distributing anonymized CT data sets to the genitourinary radiation
oncologists for delineation and utilizing the simultaneous truth and performance level estimation
(Warfield et al, 2004) to generate a consensus CTV from all of the physicians that returned
contours (Michalski et al, 2010).
Sidhom et al (2008) proposed a guideline on behalf of the Royal Australian and New
Zealand College of Radiologists, but differs from the RTOG guideline (Michalski et al, 2010) at
many of its anatomical borders. The European Organization for Research and Treatment of
Cancer endorses the guideline proposed by Poortmans et al (2007), but is a smaller target volume
than that proposed by the RTOG group (Michalski et al, 2010). The proposed guideline by
Miralbell et al (2007) is cylindrically shaped and is 4 cm high, with a 3 cm diameter and is
centered at 5 mm posterior and 3 mm inferior to the urethrovesical anastomosis and is similar to
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the guideline proposed by Poortmans et al (2007). Figure 2.1 is an example of the RTOG
guidelines as interpreted by the radiation oncologists at the London Regional Cancer Program
(LRCP) of the London Health Sciences Centre.
While the proposed consensus guidelines differ, their development has moved the field
forward by proposing definitions of an appropriate CTV that can then serve to reduce inter and
intra-observer variability among practioners adopting a given guideline.
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Figure 2.1

An interpretation of the anatomic borders of the Radiation Therapy
Oncology Group consensus guideline
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2.6 Organs at Risk

Organs at risk are normal tissues that may be exposed to radiotherapy during the
treatment of prostate cancer and may be negatively affected by the radiation. With respect to
prostate cancer, the typical organs at risk are the bladder, left femoral head, right femoral head,
penile bulb and the rectum. These organs can be susceptible to acute and late toxicity from the
radiotherapy treatment. Since the majority of irradiated prostate cancer patients live beyond 5
years, manifestations of late toxicity are very important.
Michalski et al (2000) reported on the toxicity following 3D-CRT for prostate cancer
from the RTOG 9406 study. For acute bladder toxicity, when greater than 30 percent of the
bladder was given 65 Gy or greater, these patients had a relative risk of 2.16 of developing acute
bladder toxicity (p = 0.013). For late toxicity of the bladder, when patients received 65 Gy
radiation or greater to a bladder volume that was greater than the reference, the patients were
2.19 times more likely to develop late toxicity (p = 0.044) (Michalski et al, 2000).
Late side effects of radiotherapy to the femoral heads (and pelvic bones) are uncommon,
but are possible. Emami and colleagues (1991) noted that while necrosis of the femoral head
and/or fracture of the femoral neck have been discussed in case reports, the incidence of these
events vary depending on the dose and treatment technique.
Fiorino and colleagues (2009) conducted a systematic review of the dose-volume effects
on normal tissues in external radiotherapy in the pelvic region, and found a number of studies
that correlated the dose received by the penile structure and sexual dysfunction. One of the
studies by Roach and colleagues (2004) found that patients with a median penile dose of 52.5 Gy
or greater were at a significantly higher risk of radiation-induced impotence compared to the
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patients receiving a dose less than 52.5 Gy (odds ratio = 1.98, 95% confidence interval (1.03,
3.78)).
Staffurth (2010) conducted a systematic review on the clinical evidence of IMRT
radiotherapy and reiterated the established evidence for the dose-volume relationship in the
development of late rectal toxicity. Huang et al (2002) evaluated this relationship and found that
the incidence of rectal complications was significantly correlated to the percentage of rectal
volume treated at all dose levels (60 Gy, 70 Gy, 75.6 Gy, 78 Gy) (p < 0.001). Zelefsky and
colleagues (2002) reported additional evidence to support the findings in their earlier work that
associated late rectal bleeding and the radiation given to the volume of the rectum (Zelefsky et
al, 2000).

2.7 Inter-Observer and Intra-Observer Variability in the Contouring of the
Prostate Bed

The success of radiotherapy at the prostatic fossa and paraprostatic tissues (and any site
for that matter) is dependent, in part, on the consistency and accuracy in defining the volume to
be irradiated. Several authors have studied and quantified the inter-observer variability in
delineating the CTV for radiotherapy in post-prostatectomy patients.
Mitchell and colleagues (2009) compared their usual CTV in practice to the CTV
specified by the Radiotherapy and Androgen Deprivation In Combination After Local Surgery
(RADICALS) trial to assess the effect of the protocol CTV definition on inter-observer variation.
The RADICALS CTV protocol was adapted from the proposed guidelines by Wiltshire et al
(2007). They found the overall mean CTV increased 33% from 40.6 cm3 to 53.9 cm3 after the
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adoption of the RADICALS CTV. A ratio of the maximum volume contoured to the minimum
volume contoured measured the inter-observer variability and they found that the ratio had
reduced in all patients after the introduction of the protocol. The authors also reported a
reduction in the coefficient of variation as a consequence of the improved consistency. While the
results were promising, the authors still found considerable variability among observers
(Mitchell et al, 2009).
Symon et al (2011) evaluated the inter-observer variability in the delineation of the
prostatic fossa CTV by estimating the risk of a geographical miss through comparing the
observer defined prostatic fossa CTV with locoregional failure patterns reported in the literature.
Considerable variation was reported with the anastomosis/bladder neck region and the
retrovesical space. The mean missed volume of the authors’ defined high-risk volume was 27.5%
in the bladder/base anastomosis and the retrovesical space. The risk of excluding 25% of the
prostatic fossa was 7 times more likely in prostatic volumes that were less than 30 cm (p value =
0.006). The authors reported that the volume of the prostatic fossa CTV and the identity of the
observer were associated with the geographical miss (Symon et al, 2011).
Michalski and colleagues (2010) also assessed inter-observer variability using the kappa
statistic as the measure for physician agreement. Datasets from two patients were sent to 13
physicians and 11 returned contoured datasets. The contoured CTVs showed significant variation
for each patient among the participating physicians with an overall kappa of 0.41 (p value <
0.0001) and 0.42 (p value < 0.0001) (Michalski et al, 2010). The kappa values sit on the lower
boundary of what is considered moderate observer agreement (Landis and Koch, 1977). The
apparent variability confirmed the need for the development of the consensus guidelines for the
delineation of the prostatic fossa to reduce the variability among physicians.
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Ost and colleagues (2011) published an abstract that evaluated the inter-observer
agreement among six observers in the delineation of the prostate bed for post-prostatectomy
patients according to the European Organization for Research and Treatment of Cancer
guidelines. The overall mean (range) kappa agreement for the prostate bed, corrected for chance
was 0.49 (0.35-0.62) (Ost et al, 2011). These results show moderate agreement among the six
observers, suggesting inter-observer variability was present.
Wiltshire and colleagues (2007) assessed inter- and intra-observer variability in their
development of the consensus CTV (prostate bed). Two observers were asked to contour the
magnetic resonance imaging (MRI) studies of 18 patients (Wiltshire et al, 2007). After a
minimum of one week, the two observers contoured the MRI for the second time. This procedure
was repeated with CT images. Good reproducibility in delineating the consensus CTV between
the two observers was reported. Distance-based measurements in mm in the x, y, and z
dimensions measured the amount of the inter- and intra-observer variability. Inter-observer
variability was found to be higher than intra-observer variability. Consistent inter-observer
variability was seen in the anteroposterior and superoinferior dimensions measuring a mean (SD)
distance between contours of 3.8 mm (2.2 mm) and 1.2 mm (2.3 mm) respectively. Intra
observer variability was primarily seen in the anteroposterior dimension measuring a mean (SD)
distance between contours of 0.4 mm (1.2 mm) (Wiltshire et al, 2007).
It is clear from these data that significant variability in the delineation of the CTV still
exists despite the introduction of the consensus guidelines. The emergence of computer-assisted
auto-contouring tools, specifically atlas-based segmentation tools can potentially reduce the
variability seen among physicians even further. As long as the guidelines and auto-contouring
procedures are reproducible and valid, the combination of practice guidelines and computer-
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assisted auto-contouring tools provide a potential solution to these observed variability
challenges.

2.8 Automated Atlas-Based Segmentations

Image segmentation is the process of extracting multiple features (points, lines and
measurements), regions or volumes of interest from a digital image (typically computed
tomography, CT, or magnetic resonance imaging, MRI, images). As indicated above, manual
segmentation (contouring) may be subject to considerable variability within and between
observers. Automated, computerized image segmentation could potentially reduce this variability
and generate contours more efficiently.
Pham and colleagues (2000) summarize a number of methods currently being used for
medical image segmentation in the United States. Thresholding is an approach used to segment
images by dichotomizing the image based on the image intensities. Segmentation via
thresholding is accomplished when two different structures have contrasting intensities (for
example healthy versus tumor tissue). Region growing is a technique that segments an image
based on predefined criteria (intensity information and/or edge in the image) (Pham et al, 2000).
These two methods are rarely used alone and require additional image-processing operations.
Clustering algorithms are a more popular method for image segmentation due to the lack
of “training data” required to segment images. Training data are manually segmented images to
be used as a reference for automated segmentations of new images. These algorithms use an
iteration process that alternates between segmenting an image and characterizing the properties
of image based on its intensity. Examples of clustering algorithms include the K-means
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algorithm, the fuzzy c-means algorithm and the expectation-maximization algorithm (Pham et al,
2000).
In AABS, a library/database of previously segmented images serves as the basis for
generating automated contours. In this application, a volume of interest is segmented according
to an anatomically congruent database (the atlas) via an algorithm to construct contours around a
region of interest on the corresponding medical image slice in order to build up a full 3D
representation of the corresponding region of interest.
Several methods for AABS have been proposed. The first method is the single atlas
approach to segment all images. In a single atlas approach, only one patient is inserted into the
atlas and therefore the algorithm extracts information from one atlas subject to generate the
automated contour. The second approach is the multi-atlas method that utilizes a database of pre
contoured medical images from a number of patients to select the most similar atlas subject
based on the shape of the specified anatomical sites. Multi-atlas methods are typically used over
the single atlas approach because of the improved ability to account for the variability of
anatomical regions among patients. The advantages of the multi-atlas method have been
demonstrated in other anatomical regions such as the head and neck (Teguh et al, 2010) and bee
brains (Rohlfing et al, 2004).
More important than the type of choice of the atlas (single or multi-atlas), is the
registration algorithm because it primarily determines the accuracy and efficiency of the AABS
tool. Image registration is the mapping of two images based on their spatial characteristics and
intensity for comparison or integration purposes. AABS tools often employ a deformable (nonrigid) registration algorithm to map the relevant structures of the atlas subject to the patient’s
regions of interest. Deformable registration has greater flexibility and is able to account for

26
distortions in organs such as the movement in lungs, that cause distortions on the lung and other
organs.
Once an atlas subject is chosen by the algorithm, the algorithm deformably registers the
chosen atlas subject’s CT image onto the target’s CT image. The atlas subject’s modified
contours are then transformed onto the target’s empty CT image to create an automated contour
specifically tailored to that target’s anatomical makeup. In a previous evaluation of a non-rigid
and a rigid algorithm, the non-rigid algorithm was more accurate in the delineation of the regions
of interest and was faster in generating automated contours (Piper, 2007). The author infers that
the algorithm can be applied to an assortment of purposes, such as radiotherapy treatment
planning or during prospective radiotherapy protocols. The AABS tool in this study applies a
bootstrap method to deformably register the chosen atlas contour onto the target (patient) CT
image. Bootstrapping is a computer-based method that assesses the variability of a test statistic
and allows for the estimation of models through randomized resampling of the collected data
(Efron, 1993). Figure 2.2 illustrates the AABS process of generating automated contours.
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The process of generating automated contours using an atlas-based
segmentation tool

Studies have shown the capabilities of automatic segmentation to reduce inter-observer
variability among physician contours and to reduce the contouring time for an intact prostate
gland (Lin et al, 2008; Makni et al, 2009; Pejavar, 2008). These results have also been seen in
different anatomical sites. Of particular interest, Young and colleagues (2011) conducted a study
that demonstrated AABS reduced inter-observer variability and contouring time for
postoperative endometrial cancer nodal volumes using the same AABS tool (however, it was an
older version) as the one used in the current study.
The manual contouring time for a prostate cancer case varies from physician to physician
and has been documented to be a lengthy task. Pasquier et al (2007) reported an average manual
contouring time of 30 minutes, while Lin et al (2008) reported an average time of 25 minutes.
Makni et al (2009) used MRI images of the pelvic region and reported an average manual
contouring time of 18 minutes for the delineation of the prostate gland only. For this reason, the
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potential for AABS to reduce manual contouring time becomes an advantageous outcome in the
treatment of postoperative prostate cancer. These studies report on the typical manual contouring
process by a physician, wherein the physicians contoured the CTV and ROIs on an empty CT
image. However, with the use of an AABS tool, the CTV and ROIs have already been
automatically delineated to some degree on the CT image and requires the physician to review
and edit the auto-contours. Rather than the physician starting from scratch, the physician begins
the contouring process with a semi-completed CT simulation. Contouring variability and the
extensive contouring time are the two salient issues the technology hopes to address and resolve.

2.9 Automated Atlas-Based Segmentations for Prostate Cancer

There is currently no literature on the application of AABS for the contouring of the
prostate bed in postoperative prostate cancer patients being treated with radiotherapy. Most of
the AABS literature focuses on head and neck and lung cancers, while only two articles were
found on the subject of prostate cancer and AABS (Mohamed et al, 2010; Klein et al, 2008). One
article used 2D ultrasound images of the prostate to help in the diagnosis of prostate cancer
(Mohamed et al, 2010); while the second article used 3D MRIs to delineate the prostate for
prostate cancer treatment (Klein et al, 2008). Both studies evaluated the AABS on an intact
prostate gland.
Klein and colleagues (2008) used a deformable registration of a set of manually pre
labeled atlas images (multi-atlas method) to delineate the intact prostate and seminal vesicles in
3D MRIs. They found that most of the contouring variability occurred around the tips of the
seminal vesicles and at the anterior side of the prostate. They concluded that the contours by
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human observers were superior to the automated contours for most of the regions of interest.
Klein and colleagues (2008) concluded further improvements to the automated method are
necessary. Although this particular AABS tool used by Klein and colleagues (2008) proved to be
inferior to human contours, not all tools are created equal and implementation of the tool (that is,
generation of the atlas used by the tool) may vary. Therefore, it is important to assess the
accuracy and reliability of AABS within a given institutional basis prior to its implementation for
routine clinical use.

2.10 Methods for the Technology Assessment of Atlas-Based Segmentations

Performance of AABS may depend on tool selection and/or the region/anatomic site
being studied. Though Klein et al (2008) demonstrated that the AABS method used in the study
did not meet its intended performance of being equivalent or superior to human contouring,
another AABS method may yield the desired results for the same region. Conversely, that
particular tool may perform comparably to human contours for other regions of interest. Thus
there is a need to evaluate the accuracy and reliability of AABS tools prior to their routine
clinical use on both as a tool and region/anatomic site basis. In doing so, it is crucial to have a
rigorous methodology. Ramus and colleagues (2010) proposed a methodological approach to
assess the accuracy and reliability of delineations in head and neck cancer patients; however,
there is a little current literature outlining techniques for validating AABS tools.

2.11 Contour Comparison Studies
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Contour comparison studies have become commonplace in the radiation oncology
literature because of its importance in radiotherapy planning. These studies typically analyze
variations in contouring the target volume and the regions of interest by assessing different
factors that may influence the contouring process, such as contouring guidelines, new imaging
technologies or computer assisted-contouring programs. Despite the growing literature and its
importance, there is still no widely accepted method to compare contours.
A review article by Jameson and colleagues (2010) examined contouring studies in the
context of radiation oncology and focused on the studies’ contour comparison methods. General
groups of comparison metrics were examined and they included absolute volume, centre of
volume and overall dimensions of a volume. The volume metric analyzes the volume similarities
of the contours (size comparison), but does not consider the location differences of the contours
being compared. Centre of volume (also known as centre of mass) estimates a single point that
represents the centre position of the contours in comparison, but is a metric that is rarely used
alone due to the potential for contours to possess identical centre of volumes with vastly different
volumes and shape. The dimension metric is often employed when assessing contouring
variability in relation to direction, but its effectiveness is limited to regular structures, such as the
breast (Jameson et al, 2010).
The volume overlap is another metric that measures the overlap of two or more volumes
and attempts to overcome the positional limitations of the volume metric. Optimal usefulness of
the metric is achieved when a reference volume is available for comparison. The volume overlap
metric is a relative measure and therefore cannot provide information on the size, shape or
location of the volumes in absolute units (Jameson et al, 2010).

31
For the purposes of the current study to assess the accuracy and reliability on two sets
segmentation, the Jaccard (Jaccard, 1912) and Dice (Dice, 1945) Similarity Coefficients are two
volume overlap metrics commonly found in the literature. The Jaccard Similarity Coefficient
measures the overlap over all slices included in the measurement and is calculated by taking the
intersection between the two segmentation volumes over the union of the two segmentation
volumes (Jaccard, 1912; Zijdenbos et al, 1994). The Dice Similarity Coefficient (DSC) differs
from the Jaccard Similarity Coefficient in its calculation of the spatial overlap (ratio of the
intersection to the average). The DSC is defined as (V), V2) = 2 [|Vi|n|V 2|] / [|Vi|+|V2|] where V)
and V2 represent the volumes of the first and the second contours respectively and Pi is the
intersection. Both coefficients are similar in that a value of zero represents no overlap, and a
value of one represents perfect overlap.
An expectation-maximization algorithm (Dempster et al, 1977) for the simultaneous truth
and performance level estimation (STAPLE) considers a collection of segmentations and
computes a probabilistic estimate of a ground truth (or consensus) segmentation (Warfield et al,
2004). Warfield and colleagues (2004) developed the STAPLE algorithm for direct comparisons
of human raters and algorithm performance and to assess the performance of an automated image
segmentation algorithm. The STAPLE segmentations are often used as the reference or
consensus volume for comparison purposes in contouring studies using volume overlap metrics.
Therefore, in this study, we wish to use STAPLE segmentations as the reference or consensus
volume for comparison purposes to evaluate automated- and manual contouring accuracy and
reliability using the dice similarity coefficient.
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2.12 Study Rationale

Postoperative prostate cancer patients with adverse pathologic risk factors have been
shown to have an increased risk of disease specific mortality. The indications for postoperative
treatment guide physicians in identifying the high-risk patients that can potentially benefit from
postoperative treatment. Randomized controlled trials have demonstrated the therapeutic benefits
of adjuvant radiotherapy to these high-risk patients. The improved tumor control, extended
progression-free survival and overall survival of these patients come at the cost of toxicity sideeffects. Improvements to the therapeutic ratio in these cases may be seen with the introduction of
a consensus guideline outlining the definition of the CTV for this population. The Radiation
Therapy Oncology Group (RTOG) filled this knowledge gap by proposing a consensus guideline
that defined the CTV to minimize the variability among physicians. The development and
adoption of the consensus guidelines was successful in reducing some inter-observer variability,
but it did not wholly eliminate it. AABS is a potential solution to the variability challenges. To
confidently conclude that atlas-based segmentations have successfully resolved the challenges
and should be implemented for routine clinical use, the technology must be evaluated in its
capabilities to accurately and reliably delineate the regions of interest.
Contour comparison studies have demonstrated that the manual delineation for radiation
treatment in prostate cancer patients is a lengthy, labor-intensive task and AABS may be able to
reduce the typical manual contouring process through the use of automated contours. Given the
results from the literature, evaluating the time-savings of automated contouring workflow to the
typical manual contouring process would provide additional evidence to determine whether or
not the AABS tool should be adopted for routine clinical use.

33
There is currently no literature evaluating automated atlas-based segmentations of the
prostatic fossa. In addition, there is no literature proposing a rigorous clinical trial-based
methodology to assess the accuracy and reliability of automated atlas-based segmentations in
general. The current study develops and proposes such a methodology to evaluate the accuracy
and reliability of the RTOG compliant AABS tool to generate automated contours. The
motivation in evaluating and validating such tools is-, to reduce inter- and intra-observer
variability and to reduce the typical manual contouring time by proposing a new auto-contouring
clinical workflow.
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3.0 Research Study Objectives

3.1 Primary Objectives

1. To systematically assess the accuracy and reliability of AABS for the prostate bed and
five ROIs for postoperative conformal radiotherapy in prostate cancer patients.
2. To systematically assess inter- and intra-observer variability in the contouring of the
prostate bed and five ROIs for postoperative conformal radiotherapy in prostate cancer
patients.
3. To develop a general clinical trial-based methodology for future technology assessment
studies using computer-assisted segmentation engines.

3.2 Secondary Objectives

1. To quantify the differences in contouring time between AABS versus manual contouring
of a prostate bed case.

3.3 Study Hypotheses

The overall study hypothesis is that the AABS will generate accurate and reliable
automated contours for the CTV (prostate bed) and the five ROIs (bladder, left femoral head,
right femoral head, penile bulb and rectum). It is also hypothesized that the use of the AABSs
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will ultimately lead to a reduction of inter- and intra-observer variability in the contouring of the
CTV and the five ROIs, and additionally reduce the overall contouring time.
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4.0 Methods

4.1 Overview

In 2010, the RTOG published a consensus guideline for the definition of the CTV for
postoperative conformal radiotherapy in prostate cancer patients in an attempt to minimize
variability between radiation oncologists (Michalski et al, 2010). The London Regional Cancer
Program (LRCP) of the London Health Sciences Centre provides patient care to cancer patients
in the Southwestern Ontario region. There are many active RTOG clinical trials at the LRCP and
therefore, it adheres to the RTOG guideline. The research project assessed a RTOG compliant
atlas-based deformable segmentation engine on its capabilities to generate automated contours of
the CTV (the prostate bed) and five ROIs (bladder, left and right femoral heads, penile bulb and
rectum) with a goal to ultimately reduce inter- and intra-observer variability and contouring time.
The current study also intended to develop a methodology capable of achieving the study
objectives. The project had three sequential stages. The first stage involved the construction of
the atlas. The second stage assessed the AABS on a new sample of cases and the inter-observer
variability of human contours. Finally, the third stage assessed the accuracy and reliability of the
AABS in clinical applications. A total of 80 Digital Imaging and Communications in Medicine
(DICOM) datasets were obtained from the LRCP in London, Ontario. Approval for this project
was obtained from the University of Western Ontario ethics board (see Appendix A).
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4.2 Summary of Methods

1. A literature review was conducted to explore the current status of atlas-based
segmentations of the CTV for postoperative conformal radiotherapy in prostate cancer
patients.
2. Stage One: Construction of the Atlas. A radiation oncologist known as the “atlas builder”
constructed the atlas using 75 patient CT DICOM datasets previously obtained in the
process of planning radiation treatments for postoperative prostate bed radiotherapy.
AABS were generated for each patient. Each automated contour was edited by the atlas
builder to conform to the RTOG guidelines. An initial assessment of the atlas was
performed to assess the AABS in relation to the clinical guidelines.
3. Stage Two: Assessment of the AABS and Inter-observer Variability. An expert panel of
five radiation oncologists was assembled to generate contours on the CT DICOM datasets
of a separate set of five patients to serve as comparison contours to assess the AABS and
measure inter-observer variability in the contouring of the CTV and five ROIs using the
DSC and analysis of variance (ANOVA).
4. Stage Three: Validation of the AABS. In the third stage, a blinded dataset of selected
contours (generated by the members of the expert panel, the atlas builder, AABS and
STAPLE) was sent to the expert panel to be edited as clinically necessary. The editedAABS were compared to STAPLE to assess the accuracy and reliability of the AABS in
the delineation of the CTV and the five ROIs. The intra-observer variability among the
expert panel was also assessed.
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4.3 Variables of Interest

The CTV is the prostate bed (also referred to as the prostatic fossa) and is essentially a
conceptual space that encompasses the tissues surrounding the prostate gland prior to its surgical
removal. For the purposes of this study, the CTV was defined according to the RTOG consensus
guidelines (Michalski et al, 2010). The RTOG guideline was used due to familiarity with the
guideline, as the LRCP has routinely been a top 10 accrual centre for RTOG studies. For this
study, five normal tissues were also determined to be of interest as they are routinely contoured
as avoidance structures in radiotherapy planning. They are referred to as the ROIs and included
the bladder, left and right femoral head, penile bulb, and rectum. The contoured volumes of the
prostate bed and the normal tissues were recorded in cubic centimeters (and in number of voxels
- value representing the volume element on a grid in a 3D space - for computational purposes).
Total contouring time (manual and automated) was another variable collected in order to
determine the overall clinical efficiency of the AABS tool.

4.4 Participants

A consecutive sample of 80 DICOM CT datasets was obtained from the LRCP Quality
Assurance Imaging database from January 2009 to December 2009 for retrospective
segmentation (refer to Appendix A for ethics approval). A formal sample size calculation was
not performed because there was no previous literature from which we could extract information
for the necessary parameters to estimate an appropriate sample size. Though there are numerous
studies with similar or smaller sample sizes (Klein et al, 2008; Reed et al, 2009; Teguh et al,
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2010). All of the 80 datasets were from prostate cancer patients that had a radical prostatectomy
procedure in 2009, and had undergone post-prostatectomy radiotherapy computed tomography
(CT) simulation as part of their routine radiation treatment planning. Seventy five patients were
randomly selected to be the sample for the atlas building process. The remaining five patients
functioned as the sample to assess the atlas-based segmentations and inter- and intra-observer
variability in the delineation of the CTV and the five ROIs. The sample of five patients is
comparable to the size of the sample used in other studies to test atlas-based segmentations
(Reed et al, 2009; Teguh et al, 2010). A chart review to obtain participant demographics was not
performed because of its limited relevance to the validation procedures in this report.
During the one-year period from January 2009 to December 2009, 3D CT images for
simulation radiotherapy was obtained for each patient dataset as part of their routine radiation
treatment planning. Participants were asked to have an empty rectum and a full bladder. Those
that were scanned and failed to meet the requirements were asked to evacuate their rectum and
were subsequently re-scanned. About 87% (n = 65 participants) of the scans had no bladder
contrast. All participants were scanned in the supine position, from the lumbar vertebrae L4 to
just below the ischial tuberosity. The 3D CT scans were acquired with a Philips Brilliance CT
Big Bore scanner (Philips Medical Systems, Cleveland, USA). The CT images were saved
according to the DICOM standards of practice (Bidgood et al, 1997).

4.5 Stage One: Construction of the Atlas

4.5.1 Overview
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At this stage of the research project, the aim was to develop an RTOG compliant multi
atlas that could be used for testing in the next two stages. This stage is important because the
atlas needs to be primed before it can be used to generate AABS in the subsequent stages. Of the
80 patients, 75 of them were randomly chosen and entered into the atlas. The computer-assisted
segmentation engine generated segmentations for each of the 75 patients. In general, as the
segmentation engine is a “learning” algorithm, the quality of automated segmentations should
improve with the number and quality of the segmentations in the database that it can draw upon.
Thus, especially for initial contours generated by the algorithm, reviewing and editing by a
human observer is required to ensure contours are correctly generated. The atlas builder
systematically edited each automated contour to ensure the contours complied with the RTOG
consensus guidelines. Once the edited-automated contours met the guideline requirements, the
contours were added into the atlas. To be conservative, we estimated that 75 atlas subjects would
construct a sufficiently diverse atlas database for optimal efficiency and performance, as other
studies had fewer atlas subjects (Rohlfmg et al, 2004; Teguh et al, 2010). Rohlfing et al (2004)
inserted only 19 atlas subjectsto evaluate strategies for the selection of atlas subjects in atlasbased segmentations.

4.5.2 Automated Atlas-Based Segmentation Engine

MIM (MIMvista Corp, Cleveland, USA) was the atlas-based segmentation engine
assessed in the current study. The engine is intended to be used by trained medical professionals
as a tool to aid in the segmentation and evaluation of digital medical images. It allows users to
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display, register and fuse medical images from multiple modalities, such as CT images and to
create, transform and modify contours.
The atlas is a database of pre-contoured CT images that compares a given patient’s image
(destination patient) to the images of the atlas subjects to find the best anatomical match. Once a
match is found, the chosen atlas subject’s pre-contoured CT image is deformably registered onto
the destination patient’s CT image. The contours from the atlas subject’s pre-contoured CT
image are transformed onto the destination patient’s empty CT image using the parameter from
the deformable CT image registration to produce the automated atlas-based segmentation.
Additional inputs to the algorithm include the scanning area of interest on the superior and
inferior axis and for this study it was set to be inferior to the lumbar vertebrae L5 and S1 to
superior to the area just below the ischial tuberosity. Occasionally, the atlas builder was required
to modify the parameter based on the participant’s anatomy to include the prostate bed.
MIMVista uses a VoxAlign Deformation Engine (MIMvista Corp, Cleveland, Ohio) that
has a unique constrained intensity-based free-form deformable registration algorithm for CT-CT
registrations and can be applied to generate the atlas-based segmentations (Piper, 2007).
MIMVista’s algorithm incorporates a bootstrap methodology to create deformable registered
atlas-based contours. The deformable (non-rigid) algorithm has previously been evaluated
against a rigid registration method and was shown to have greater accuracy and a quicker auto
contour generation speed (Piper, 2007). The MIMVista software package was installed onto a
3.06 GHz dual core Macbook Pro computer, and all auto-contours were generated using this
computer. Though the algorithm is robust (Piper, 2007), the initial automated contour still
requires careful inspection by a physician.
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4.5.3 Atlas Building Process

The procedures for the creation of the atlas were as follows:
1. A patient was randomly chosen to become the index case. The atlas builder manually
contoured the index case as per the RTOG guidelines and inserted the contoured CT
image into the atlas.
2. A second patient was randomly selected to have the MIM atlas-based segmentation
engine generate an automated contour. Since the index case was the only possible
match in the atlas, the algorithm selected the index case as the best match.
3. Once the best match was chosen, the algorithm engine deformably registered the
atlas subject’s pre-contoured CT image to the patient’s empty CT image. The atlas
subject’s pre-contoured CTV and the five ROIs were warped and transformed onto
the patient’s empty CT image to create a tailored automated contour.
4. The elapsed time for the first 3 steps was recorded to assess the learning curve
associated with the building of an atlas.
5. The auto-contour for the prostate bed, bladder, left and right femoral head, penile
bulb and rectum was edited by the atlas builder according to the RTOG guidelines.
The time required to edit the CTV and the five ROIs was recorded.
6. The final contour was then added to the atlas database, totaling 2 atlas subjects.
7. The remaining 73 patients were selected at random and steps 2 to 6 were repeated for
each patient.
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8. A second radiation oncology professional audited the final contours to ensure all
contours complied with the RTOG consensus guidelines for the delineation of the
prostate bed.
Figure 4.1 depicts the atlas building process.
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Atlas building process
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4.6 Stage Two: Assessment of the Automated Atlas-Based Segmentations and InterObserver Variability

4.6.1 Overview

Of the 80 patients, five patients were randomly selected to be used to assess the atlasbased segmentation engine and the inter-observer variability in the delineation of the CTV and
five ROIs. An expert panel consisting of five radiation oncologists that routinely contour prostate
bed cases at the LRCP was assembled. Data was gathered from the expert panel’s contours to
create the simultaneous truth and performance level estimation (referred to as STAPLE) contours
to act as the consensus “gold standard” contours. Inter-observer variability was assessed and
baseline measurements were established to assist in the assessment of intra-observer variability
at the third stage.

4.6.2 Observers (Human Raters)

A total of six radiation oncologists were involved in the contouring processes. The atlas
builder has been a fully trained radiation oncologist at the LRCP for 10 years and is a member of
the RTOG Genitourinary Subcommittee. An additional five licensed radiation oncologists that
vary in experience were gathered to formulate the expert panel. The expert panel consists of
members within the LRCP with 16, 10, 10, 4 and 2 years of post-residency experience. The atlas
builder was not part of this expert panel.
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4.6.3 The Simultaneous Truth and Performance Level Estimation

The simultaneous truth and performance level estimation (STAPLE) measures the
performance of human and algorithmic raters in their generation of segmentations of medical
images and estimates a “ground truth” or consensus segmentation through the STAPLE
algorithm (Warfield et al, 2004). The expected maximization algorithm uses a specified
collection of local segmentations to compute a probabilistic estimate of a true segmentation by
weighing segmentations on its estimated performance level (Warfield et al, 2004). Warfield et al
(2004) has validated the use of the algorithm for image segmentation and its application to assess
the performance of AABS or to compare human observers to automated images. Figure 4.2
illustrates the general concept of the STAPLE algorithm.
The source code for the STAPLE algorithm was obtained with permission from Warfield
(2004) at Harvard University. Our DICOM data required format alterations prior to being
inputted into the algorithm due to the algorithm only reading data in a NlfTi format (another data
format used in neuroimaging). A trained medical physicist at the LRCP created the data format
alteration process. A Windows graphical user interface (GUI) called the STAPLE Umbrella was
created internally at the LRCP to simplify this process. Before the end-user could command the
GUI to start the generation of the STAPLE contour process, the user was required to set the
desired default parameters (such as motion, and the number of contouring iterations).
To generate a STAPLE contour, we first instructed the STAPLE Umbrella GUI to create
a template of the space occupied by the contours using a computer program (Yushkevich et al,
2006). Then we commanded the GUI to run another computer program that converted the
DICOM files into NifTi files (Dowling et al, 2009). The NlfTi files are inserted into the
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STAPLE algorithm software for the analysis of the CTV and ROI contours. A third computer
program converted the NlfTi STAPLE contour file back to DICOM files for analysis (Gorthi et
al, 2009). Figure 4.3 depicts the entire process of generating the STAPLE contours.

Three different segmentations

Estimated true (or consensus) segmentation
STAPLE

Figure 4.2

The concept of the STAPLE algorithm

STAPLE is the Simultaneous Truth and Performance Level Estimation proposed by Warfield et al (2004).

I
End

Figure 4.3

Procedure for creating STAPLE contours from DICOM files

STAPLE is the Simultaneous Truth and Performance Level Estimation proposed by Warfield et al (2004).
GUI is the graphical user interface.
DICOM is the Digital Imaging and Communications in Medicine.
ROI is the regions o f interest.
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4.6.4 Assessment of Automated Atlas-Base Segmentations and InterObserver Variability Process

A new sample was required to assess the accuracy and performance of the AABS tool. It
presented the atlas with the challenge of creating an automated atlas-based segmentation for
patients with anatomical shapes likely not seen by the atlas. Each member from the expert panel
was asked to contour the CT images from the five patients. The dataset was anonymized and sent
with a data sheet with instructions (see Appendix B) to the expert panel and the atlas builder. The
atlas builder also contoured this dataset to assess the appropriateness of the chosen atlas builder
and for its use in the third (validation) stage.
The data sheet included instructions regarding the location of the CT images to be
contoured on the Philips Pinnacle treatment planning system (Philips, Fitchburg, Wisconsin), and
the process to which contouring should be completed. The RTOG CTV guideline for the prostate
bed was also provided to the physicians. ROIs labels for the prostate bed, bladder, rectum,
bilateral femora and penile bulb were identified in Pinnacle to indicate the areas of interest to be
contoured by the expert panel and atlas builder. The methodological process for stage two are as
follows:
1. The expert panel and the atlas builder were asked to manually contour the prostate
bed, the left and right femoral head, the bladder, the penile bulb and the rectum for
the five patients on the Philips Pinnacle system and to record the time required to
contour each patient.
2. Atlas-based deformable segmentations were generated for the five patients and the
time to generate the segmentations was recorded.
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3. STAPLE contours were generated for each structure in each patient using data from
the expert panel through the STAPLE Umbrella GUI.
4. All of these contours went into a database for the final validation stage.
Figure 4.4 depicts the process for stage two.
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Assessment of the automated atlas-based segmentations and inter-observer
variability

STAPLE is the Simultaneous Truth and Performance Level Estimation proposed by Warfield et al (2004).

4.7 Stage Three: Validation of the Automated Atlas-Based Segmentations

4.7.1 Overview
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The human (their own and the atlas builder) and non-human (STAPLE and MIM)
contours from stage two were anonymized and sent back to the expert panel to be edited as
clinically necessary to assess the intra-observer variability in the delineation of the CTV and five
ROIs and to assess the accuracy and reliability of the edited automated contours.

4.7.2 Stage Three Contouring Process

The expert panel was sent an anonymized data set consisting of contours that were
created by themselves, the atlas builder, the STAPLE algorithm and the AABS engine. A data
collection sheet with instructions was sent to each of the members in the expert panel (see
Appendix C). They were instructed to determine whether the contour was clinically acceptable
(yes or no). They were also instructed to make any clinically necessary changes to the contours,
and record the editing time. Finally, they were asked to identify the contour’s original creator as:
own, another radiation oncologist (in this case, the atlas builder), MIM, STAPLE or indicate that
they were unsure.

4.7.3 Validation of the Automated Atlas-Based Segmentations Process

The validation of the AABS compares the final edits of the automated contours by the
expert panel to the estimated consensus contour, STAPLE. If the edited automated contour
converges toward the STAPLE segmentation, we have evidence that the atlas can be used to
generate initial segmentations for postoperative conformal radiotherapy. The dice similarity
coefficient (DSC) will measure the performance of the edited automated contours to the
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STAPLE segmentations. We hypothesized that the AABS may require the most editing, while
the STAPLE segmentations and their own contours would require the least due to the consensus
and familiar nature of the contours, respectively.
The following was the executed process for the validation of the AABS:
1. Strategic datasets of contours (gathered from stage two) were sent to the expert
panel. Each member was sent contours created by them self, the atlas builder, the
STAPLE algorithm and the AABS tool. For example, MDi receives contours created
by MDi, the atlas builder, STAPLE and the AABS tool for all five patients. MD2
receives contours created by MD2, the atlas builder, STAPLE and the AABS tool for
all five patients. Similar datasets were distributed to the remaining members.
2. The expert panel was instructed to determine if the contour was clinically acceptable
(yes or no), make clinically necessary changes to the contours, to identify the creator
of each contour (own, other radiation oncologist, STAPLE, AABS or don’t know)
and to record the time required to edit the contours. The atlas builder contours were
labeled as the “other radiation oncologist”.
Figure 4.5 depicts the process for this stage.
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4.8 Statistical Analysis

The SAS (SAS Institute Inc, North Carolina, USA) and StructSure (Standard Imaging
Inc, Wisconsin, USA) software packages were used to perform all the statistical and overlap
analyses, respectively.

4.8.1 Validation Metric - Dice Similarity Coefficient

The dice similarity coefficient (DSC) is a simple spatial overlap index that was first
proposed by Dice (1945). DSC is defined as (V 1/V2) = 2 |VifiV2I / [|V 1I+IV2I], where Vj and V2
represent the volumes of the first and the second contours respectively and fl is the intersection,
see Figure 4.6. The DSC range from 0 to 1, representing no spatial overlap between two sets of
segmentation results to complete spatial overlap. The current study assessed the accuracy and
reliability of segmentations from both human and automated non-human raters. The DSC has
been demonstrated to be a useful summary measure for the measurement of spatial overlap and
can be applied to studies assessing the accuracy and reliability of image segmentations by human
or automated raters (Zou et al, 2004).
An analysis of variance (ANOVA) carries a number of assumptions and of particular
interest is the assumption of a normally distributed outcome variable. Since the DSC tends to
cluster towards 1, the assumption of a normal distribution may not hold, rendering the statistical
inferences from the ANOVA results questionable. The Shapiro-Wilk test (Shapiro and Wilk,
1965) was performed to test for the normal distribution of the DSC. If the results are found to be
non-normal, Zou et al (2004) suggests the DSC be logit-transformed to satisfy the assumption of
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a normal distribution. The distribution of the logit-transformed values was shown to
asymptotically follow a normal distribution for a large number of voxels (Agresti, 1990). The
transformation changes the DSC range (0, 1) to an unbounded range (-go, co), where logit(DSC) =
ln{DSC/(l-DSC)} and logit(0.5) = 0. Zijdenbos et al (1994) recommends that a DSC > 0.70 or a
logit(DSC) > 0.847 is considered to be good overlap.

DSC = 2|V,nV2|/[|V,|+|V2|]

Spatial Overlap of Two
Volumes: V| and V2

Figure 4.6
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4.8.2 Statistical Analysis - Stage One: Construction of the Atlas

Descriptive statistics and Pearson correlation coefficients were calculated to explore the
performance, efficiency and potential learning curve of the AABS tool (DSC versus the number
of patients in the atlas and the number of patients in the atlas versus the time to generate
automated contours). The calculated DSC compared the initial atlas-based deformable
segmentations to the final edited version of the automated contours to gain insights on the
performance of the AABS to generate RTOG compliant automated contours. One-way quintile
ANOVA assessed the contouring time in relation to the number of patients in the atlas to
evaluate the potential learning curve of the AABSs. Teguh et al (2010) inserted only 10 patients,
Sims et al (2009) inserted only 13 patients, and Young et al (2011) inserted 15 patients into their
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atlas databases. Based on these two similar auto-contouring studies, equal groups of 15 would
give a conservative estimate on the performance of the learning algorithm as more cases are
added to the atlas. Shapiro-Wilk test for normal distribution was performed on the calculated
DSC. Quintile ANOVA using logit(DSC) assessed the performance of the AABS engine to
generate RTOG compliant segmentations for every 15 patients added to the atlas. Bonferroni
correction was used to adjust for multiplicity in the quintile comparisons (Hochberg, 1988).

4.8.3 Statistical Analysis - Stage Two: Assessment of the Automated AtlasBased Segmentations and Inter-Observer Variability

The DSC was calculated to assess the AABS, inter-observer variability and the
appropriateness of the atlas builder. Descriptive statistics were calculated to illustrate overall
inter-observer variability.
Shapiro-Wilk test for normal distribution was performed on the calculated DSC. One
way analysis of variance was performed using logit(DSC) to test for inter-observer variability in
the delineation of the CTV and five ROIs among the expert panel. Two-way ANOVA was
performed modeling the effects of the observer and the patient on logit(DSC) values for the CTV
and five ROIs, and the effects of the observer and the patient case on the manual contouring
time.

4.8.4 Statistical Analysis - Stage Three: Validation of the Automated AtlasBased Segmentations
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The DSC was calculated for a number of spatial overlap comparisons to determine the
convergence of the edited automated contours and intra-observer variability in the delineation of
the CTV and five ROIs. Descriptive statistics were calculated to describe the performance of the
automated atlas-based segmentation engine using DSC and the contouring time for human
observers and non-human raters. The time analysis compares the time spent contouring a CT
image by a radiation oncologist through a typical manual contouring process in which the
radiation oncologist contours an empty CT image versus the time spent editing the CTV and
ROIs of an automated contour that had been previously delineated by the AABS to some degree
(from stage three). Figure 4.7 depicts this time analysis. The paired t-test was used to assess the
differences in the contouring times.

Time spent editing the automated contours by the expert panel

Vs.

M a n u a l c o n t o u r i n g tim e b y th e e x p e r t p a n e l in s ta g e 2

Figure 4.7

Illustration of the time analysis from a clinical perspective

4.9 Attempts to Minimize Bias

Four measures were taken to minimize bias. The first attempt to eliminate bias occurred
at the construction of the RTOG atlas stage through the appraisal of the edited contours by a
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second radiation oncology professional to ensure compliance. Calculating the DSC between the
atlas builder and STAPLE contours at stage two to evaluate the appropriateness of that particular
radiation oncologist as the atlas builder was the second attempt. Quantitatively comparing the
atlas builder to the consensus contour provided evidence that the atlas builder contours according
to the RTOG guidelines and compares reasonably to a community of radiation oncologists.
Sending the expert panel the strategic anonymized blinded dataset to be assessed in stage three
was the third attempt to minimize bias. The expert panel was blinded to gather data to assess
intra-observer variability and to hopefully prevent any preconceptions the expert panel may have
had if they knew the creator of the contour. Finally, waiting four weeks after the expert panel
finished stage two before sending the anonymized dataset to the expert panel to be reviewed was
designed to prevent the members from easily recalling their own contours.
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5.0

Results

5.1 Stage One: Construction of the Atlas

The Radiation Therapy Oncology Group (RTOG) compliant atlas was created by a
radiation oncologist (known as the atlas builder) and consisted of 75 DICOM datasets and all of
the datasets were successfully entered into the atlas. Generating automated atlas-based
segmentations (AABS) for the 75 patients took an average of 108 seconds (standard deviation
(SD)) = 25 seconds, range 68 to 200 seconds). Quintile analysis of variance (ANOVA) suggests
no statistically significant improvements in auto-contouring time as the number of subjects
increased in the atlas (p value = 0.28). The mean (SD) for the auto-contouring time for quintile 1,
2, 3, 4, and 5 was 103 (37), 97 (11), 109 (27), 114 (23) and 115 (22) seconds respectively. Figure
5.1 illustrates the Pearson correlation coefficient between the number of subjects in the atlas and
the automated atlas-based contouring time, r = 0.20 (two-tailed p value = 0.093). The result
suggests a failure to reject the null hypothesis of no correlation between auto-contouring time
and the number of subjects in the atlas. We can expect that the AABS auto-contouring time to
remain consistent throughout.
The mean (SD) time it took the atlas builder to edit the automated contours to comply
with RTOG guidelines for the clinical target volume (CTV) and each of the regions of interest
(ROI) was 154 seconds (71 seconds) for the prostate bed, 156 seconds (79 seconds) for the
bladder, 125 seconds (80 seconds) for the left femoral head, 97 seconds (61 seconds) for the right
femoral head, 19 seconds (9 seconds) for the penile bulb and 149 seconds (65 seconds) for the
rectum. The editing time for the CTV and the five ROIs all decreased over time (see Appendix D
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for graphical representation of the CTV and ROIs). The dice similarity coefficient (DSC) was
calculated to compare the edited-AABS by the atlas builder to the initial AABS generated by the
tool. The mean (SD) DSC for the CTV and the ROI was 0.65 (0.16) for the prostate bed, 0.73
(0.18) for the bladder, 0.95 (0.04) for the left femoral head, 0.96 (0.04) for the right femoral
head, 0.60 (0.28) for the penile bulb and 0.68 (0.13) for the rectum.
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Figure 5.1

Correlation between the number of subjects in the atlas and the autocontouring time

The relationship between the number of atlas subjects and DSC yielded Pearson
correlation coefficients r = 0.06 (p value = 0.629) for the prostate bed, r = 0.32 (p value = 0.006)
for the bladder, r = 0.48 (p value < 0.001) for the left femoral head, r = 0.36 (p value = 0.002) for
the right femoral head, r = 0.28 (p value = 0.016) for the penile bulb and r = 0.10 (p value =
0.406) for the rectum. The correlation between the number of subjects and the bladder, left
femoral head, right femoral head and the penile bulb were significant, suggesting the correlation
among these comparisons does not equal zero. The prostate bed and rectum failed to show
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similar findings. Table 5.1 illustrates the descriptive statistics for the quintile analysis (n = 15 per
group) for every 15 patients added to the atlas for each ROI and the CTV to evaluate the
performance of the AABS as more subjects are added to the atlas. The Shapiro-Wilk test for the
CTV and the five ROIs were all statistically significant (p < 0.001). We can reject the notion that
the DSC was normally distributed and as a result the analysis of DSC required logit
transformations. The quintile ANOVA results in Table 5.2 illustrates the performance of the
AABS tool for every 15 patients that are added to the atlas. In Table 5.2, the bladder, left femoral
head and right femoral head suggests that at least one quintile significantly differs from another
quintile.
Table 5.1

The ability of the automated atlas-based segmentation tool to generate
segmentations compliant with the consensus guidelines as more subjects are
added to the atlas

Variables

Quintile 1

Quintile 2

Quintile 3

Quintile 4

Quintile 5

DSC mean (SD)
Prostate Bed

0.63 (0.13)

0.64 (0.20)

0.63 (0.17)

0.71 (0.13)

0.66 (0.16)

Bladder

0.58(0.15)

0.75 (0.16)

0.74 (0.20)

0.84 (0.10)

0.72 (0.17)

LFH

0.90 (0.07)

0.96 (0.02)

0.96 (0.02)

0.97 (0.02)

0.97 (0.02)

RFH

0.93 (0.04)

0.94 (0.04)

0.97 (0.01)

0.97 (0.01)

0.96 (0.04)

Penile Bulb

0.37(0.39)

0.65 (0.23)

0.60 (0.27)

0.72 (0.13)

0.64 (0.23)

Rectum

0.62 (0.12)

0.72 (0.15)

0.66 (0.15)

0.71 (0.13)

0.68 (0.11)

DSC is the dice similarity coefficient.
SD represents standard deviation.
LFH is the left femoral head.
RFH is the right femoral head.

Table 5.2

Quintile ANOVA using logit(DSC) to assess performance of the atlas-based segmentation tool for every 15
patients added to the atlas

Comparison

Prostate

Bladder

Left Femoral Head

Right Femoral Head

<0.001

<0.001

0.004

1 -2

-0.88 (-1.85, 0.09)

-0.81 (-1.43,-0.18)*

-0.27 (-1.01,0.46)

1-3

-1.03 (-1.99, -0.06)*

-0.82 (-1.45,-0.20)*

-0.76 (-1.49, -0.03)*

1 -4

-1.50 (-2.47,-0.53)*

-1.31 (-1.93,-0.68)*

-0.83 (-1.56, -0.10)*

1 -5

-0.76 (-1.73,0.21)

-1.11 (-1.73,-0.45)*

-0.78 (-1.51,-0.05)*

2 -3

-0.14 (-1.09, 0.81)

-0.02 (-0.63, 0.59)

-0.49 (-1.21,0.23)

2 -4

-0.62 (-1.57, 0.33)

-0.50 (-1.11,0.11)

-0.55 (-1.27, 0.16)

2 -5

0.12 (-0.83, 1.08)

-0.31 (-0.92, 0.31)

-0.51 (-1.22, 0.21)

3 -4

-0.47 (-1.43,0.48)

-0.48 (-1.09,0.13)

-0.07 (-0.79, 0.65)

3 -5

0.27 (-0.68, 1.21)

-0.29 (-0.90, 0.32)

-0.02 (-0.74, 0.70)

4 -5

0.74 (-0.21, 1.69)

0.19 (-0.42, 0.81)

0.05 (-0.67, 0.77)

0.607

Difference
between quintile
means (95% C.I.)

DSC is the dice similarity coefficient
C.I. is the confidence interval

Rectum

Bulb

Bed
ANOVA p value

Penile

0.338

0.150
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5.2 Stage Two: Assessment of the Automated Atlas-Based Segmentations and InterObserver Variability

5.2.1 Performance of the Automated Atlas-Based Segmentations on New
Cases

In this stage, 5 new subjects were used to test the performance of the atlas and inter
observer variability. Table 5.3 illustrates the descriptive statistics for the DSC evaluating the
MIM generated auto-contours against the consensus contour (the simultaneous truth and
performance level estimation (STAPLE)) and the expert panel. The MIM AABS tool had higher
mean DSCs for the CTV and the five ROIs when compared to the STAPLE consensus contour
than when compared to the human observers. In regards to variability, the AABS tool appears to
have less variability in the bilateral femoral heads when compared to STAPLE. The variability
between the AABS versus STAPLE and the AABS versus the expert panel for the prostate bed,
bladder, penile bulb and the rectum regions are comparable.
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Table 5.3

Assessing performance of the auto-contours using dice similarity coefficient
for the clinical target volume and the regions of interest

Variables

AABS vs. STAPLE

AABS vs. Expert Panel

Prostate Bed

0.48 (0.17, 0.18-0.59)

0.47 (0.16,0.11 -0.64)

Bladder

0.67 (0.19, 0.34-0.80)

0.67 (0.18,0.33 -0.81)

Left Femoral Head

0.92 (0.01,0.92-0.93)

0.83 (0.18,0.43 -0.93)

Right Femoral Head

0.92 (0.01,0.91 -0.93)

0.83 (0.17,0.45-0.94)

Penile Bulb

0.33 (0.25, 0.10-0.70)

0.31 (0.23,0-0.78)

Rectum

0.59(0.11,0.48-0.77)

0.58 (0.09,0.45-0.77)

Mean DSC (SD, Range)

AABS represents the automated atlas-based segmentations.
STAPLE is the Simultaneous Truth and Performance Level Estimation proposed by Warfield et al (2004).
DSC is the dice similarity coefficient.
SD represents standard deviation.

5.2.2 Inter-Observer Variability

Table 5.4 illustrates the descriptive statistics for the DSC evaluating the inter-observer
variability by comparing the observers to the truth (STAPLE) and by comparing the observers to
each other. Contrary to the results in Table 5.3 that reported the bilateral femoral heads with the
highest mean DSC, the bladder ROI obtained the highest DSC in both comparisons of 0.96 and
0.94 and had the smallest amount of variation with standard deviations of 0.02 and 0.03 for the
STAPLE versus observers and observers versus observers comparisons respectively. The rectum
ROI had the second highest DSC and second lowest amount of variation. Though most of the
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ROI had a high mean DSC, they also had high standard deviations and wide ranges (except for
the bladder and rectum). Figure 5.2 illustrates the variability among the expert panel in the
contouring of the CTV and the ROIs.
The Shapiro-Wilk test for the CTV and the five ROIs were all statistically significant (p <
0.001). Therefore, we can reject the notion that the DSC was normally distributed and as a result
the analysis of the DSC required logit transformations. Table 5.5 illustrates the logit(DSC)
transformations that were performed, then used in an ANOVA analysis to test for inter-observer
variability. All models included all 100 observations, except for the penile bulb. Eight
observations were omitted for the penile bulb because there were eight DSC = 0, and
consequently logit transformations could not be completed. We expected that there would be
some variability among the ROI, particularly the prostate bed. We did not a priori expect much
variability among the observers when contouring the bilateral femoral heads. The results from
Table 5.5 suggest there was at least one observer that significantly differed from the other
observers when contouring the prostate bed (p value = 0.002), left femoral head (p value <
0.001) and right femoral head (p value < 0.001). There was no significant difference among
observers when contouring the bladder, penile bulb and the rectum.
Table 5.6 presents the results of the two-way ANOVA modeling the effects the observer
and patient on the DSC. The full two-way model for the prostate bed was statistically significant
(p < 0.001). There is also sufficient evidence to suggest that the observer (p < 0.001) and the
patient (p = 0.006) both have a significant effect on the DSC. The inclusion of both the observer
and patient in the full model explains 29% of the variation in the DSC. The full two-way model
for the bladder was statistically significant (p < 0.001). Both the observer (p = 0.002) and the
patient (p < 0.001) have a significant effect on the DSC. Accounting for both the observer and
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the patient in the full model explains 88% of the variation in the DSC. The full two-way model
for the left and right femoral head had near identical results, both were shown to be statistically
significant (p < 0.001). There is evidence to suggest that the observer had a significant effect on
the DSC for the bilateral femoral heads (p < 0.001). The patient however, did not have a
significant effect on the DSC for the bilateral femoral heads. For the bilateral femoral heads, the
inclusion of both the observer and the patient explained 37% of the variation in the DSC. The
full two-way model for the penile bulb was statistically significant (p < 0.001). The evidence
suggests that the observer does not have a significant impact on DSC. The patient however
significantly effects the DSC (p < 0.001) for the penile bulb. The full model was able to account
for 44% of the variation in the DSC. The full two-way model for the rectum was statistically
significant (p < 0.001). The observer did not have a significant effect on the DSC, while the
patient significantly affected the DSC (p < 0.001). Incorporating the observers and patients into
the model explained 42% of the variation in the DSC.
Table 5.7 presents the results of the two-way ANOVA analysis modeling the effects of
the observers and patients on the manual contouring time. The full two-way model for the
manual contouring time was significant (p < 0.001). Both the observers (p < 0.001) and the
patients (p < 0.001) had a significant effect on the contouring time. The two variables were able
to account for 83% of the variation seen in the contouring time.
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Table 5.4

Overview of inter-observer variability using dice similarity coefficient for the
clinical target volume and regions of interest

STAPLE vs. Expert Panel

Inter-Observer Variability
Between the Expert Panel

Prostate Bed

0.78 (0.15,0.37-0.91)

0.65 (0.14,0.29-0.84)

Bladder

0.96 (0.02,0.92-0.98)

0.94 (0.03,0.87-0.97)

Left Femoral Head

0.87(0.19, 0.47-0.98)

0.76 (0.23, 0.42 - 0.99)

Right Femoral Head

0.87 (0.19, 0.46-0.98)

0.77 (0.23,0.46-0.99)

0.70 (0.17,0-0.88)

0.55 (0.22,0-0.84)

0.89 (0.06,0.67-0.94)

0.83 (0.07,0.65-0.91)

Variables
Mean DSC (SD, Range)

Penile Bulb
Rectum

STAPLE is the Simultaneous Truth and Performance Level Estimation proposed by Warfield et al (2004).
DSC represents the dice similarity coefficient.
SD represents standard deviation.

00

lO

Figure 5.2

Axial and sagittal computed tomography image demonstrating individual contours from the expert panel
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Table 5.5

One-way ANOVA using logit(DSC) to assess inter-observer variability in the
manual delineation of the clinical target volume and the regions of interest
among the expert panel

Model DF

Error DF

F Statistic

P value

Prostate Bed

4

95

4.58

0.002

Bladder

4

95

0.60

0.665

Left Femoral Head

4

95

13.04

<0.001

Right Femoral Head

4

95

13.28

<0.001

Penile Bulb

4

87

1.22

0.309

Rectum

4

95

1.48

0.215

Region of Interest

Logit(dice similarity coefficient) was used in these one-way ANOVA models.
DF is the degrees o f freedom

Table 5.6

Two-way ANOVA modeling the effects of the observers and patients on the dice similarity coefficient

Regions of Interest

Model DF

Error DF Corrected Total DF

F Value

P value

R2

4.53

<0.001

0.285

Prostate Bed
Full Model

8

91

99

Main Effects
Observers

4

5.14

<0.001

Patients

4

3.92

0.006

84.97

<0.001

Bladder
Full Model

8

91

99

0.882

Main Effects
Observers

4

4.73

0.002

Patients

4

165.21

<0.001

6.74

<0.001

Left Femoral Head
Full Model

8

91

99

0.372

Main Effects
Observers

4

12.84

<0.001

Patients

4

0.64

0.6368

Logit(dice similarity coefficient) was used in this ANOVA analysis.
DF is the degrees o f freedom.
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Table 5.6

Two-Way ANOVA modeling the effects of the observers and patients on the dice similarity coefficient
(continued...)

Regions of Interest

Model DF

Error DF Corrected Total DF

F Value

P value

R2

6.62

<0.001

0.368

Right Femoral Head
Full Model

8

91

99

Main Effects
Observers

4

12.91

<0.001

Patients

4

0.33

0.857

8.25

<0.001

Penile Bulb
Full Model

8

83

91

0.443

Main Effects
Observers

4

1.98

0.106

Patients

4

14.52

<0.001

8.06

<0.001

Rectum
Full Model

8

91

99

Main Effects
Observers

4

2.27

0.067

Patients

4

13.84

<0.001

Logit(dice similarity coefficient) was used in this ANOVA analysis.
DF is the degrees o f freedom.

0.415

Table 5.7

Two-way ANOVA modeling the effects of the observers and patients on manual contouring time

Variance

Model DF

Error DF Corrected Total DF

F Value

P value

R2

9.46

<0.001

0.826

Component
Full Model

8

16

24

Main Effects
Observers

4

10.72

<0.001

Patients

4

8.21

<0.001

DF is the degrees o f freedom

NJ
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5.3 Stage Three: Validation of the Automated Atlas-Based Segmentations

Table 5.8 displays the results of the AABS validation. The DSC compared the edited
auto-contours by the expert panel to the consensus contour, STAPLE. The highest spatial overlap
was seen in the bilateral femoral heads, followed by the bladder, rectum and the prostate bed.
The lowest spatial overlap was seen in the penile bulb. These results are consistent with those
seen in stage 2 that compared the unedited auto-contours to STAPLE.
In addition to the validation results, Table 5.8 displays a summary of the DSC for the
AABS tool’s initial automated contours, the expert panel’s contours and the atlas builder’s
contours to the consensus contours. The spatial overlap analysis between the atlas-builder and
STAPLE helps to determine if the atlas-builder contoured the CTV and ROIs as the community
of radiation oncologists would contour these regions. For the CTV and the five ROIs, the atlas
builder had the highest mean DSC and the lowest variation among the other comparisons.
Therefore, the atlas builder proved to be an appropriate individual to construct the RTOG
compliant atlas.
Prior to any editing of the stage 2 contours by the expert panel, they were asked if the
contour was acceptable (yes or no). Out of the 50 human contours, 78% was considered
clinically acceptable. Out of the 25 STAPLE contours, 96% was considered clinically
acceptable. Out of the 25 MIM auto-contours, 12% was considered clinically acceptable. The
expert panel was also asked to identify the creator of the contours. Out of the 50 MIM and
STAPLE contours, 54% was correctly identified. Out of the 50 human (own and atlas builder)
contours, 70% was correctly identified as human contours. Out of 25 contours, the expert panel
was able to identify their own contours 56% of the time.

Table 5.8

Summary table illustrating the dice similarity coefficient of the automated atlas-based segmentations and the
manual contours compared to consensus contours (STAPLE)

Variables

AC vs. STAPLE

Edited-AC vs. STAPLE

MC vs. STAPLE

Atlas Builder vs.
STAPLE

Mean DSC (SD, range)
Prostate Bed

0.48 (0.17,0.18-0.59)

0.67 (0.19, 0.18-0.91)

0.78 (0.15,0.37-0.91)

0.93 (0.03,0.90-0.96)

Bladder

0.67 (0.19, 0.34-0.80)

0.88 (0.13,0.34-0.97)

0.96 (0.02, 0.92-0.98)

0.97 (0.01,0.95-0.99)

Left Femoral Head

0.92 (0.01,0.92-0.93)

0.93 (0.01,0.92-0.97)

0.87(0.19, 0.47-0.98)

0.96 (0.01,0.95-0.98)

Right Femoral Head

0.92 (0.01,0.91 -0.93)

0.92 (0.01,0.90-0.96)

0.87 (0.19,0.46-0.98)

0.97 (0.01,0.95-0.98)

Penile Bulb

0.33 (0.25,0.10-0.70)

0.54 (0.21, 0.10-0.78)

0.70 (0.17, 0 -0 .8 8 )

0.84 (0.07, 0.75-0.94)

Rectum

0.59 (0.11,0.48-0.77)

0.78 (0.12,0.49-0.90)

0.89 (0.06,0.67-0.94)

0.94 (0.02,0.92-0.96)

AC is the auto-contours generated from the MIM atlas-based segmentation tool.
MC is the manual contours from the expert panel.
STAPLE is the Simultaneous Truth and Performance Level Estimation contours proposed by Warfield et al (2004).
DSC is the dice similarity coefficient.
SD is the standard deviation.
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5.3.1 Intra-Observer Variability

Table 5.9 illustrates the results for the intra-observer variability analysis. The expert
panel was sent an anonymous dataset and was asked to edit the contours as clinically necessary.
Based on the high mean DSC results, there appears to be little intra-observer variability among
the expert panel. The penile bulb had the lowest mean DSC, but 0.89 is still very high and is
considered good spatial overlap.

Table 5.9

Results of intra-observer variations in contouring the clinical target volume
and the regions of interest for postoperative conformal radiotherapy in
prostate cancer patients

Region of Interest

Mean DSC (SD)

DSC Range (Min-Max)

Prostate Bed

0.93 (0.04)

0.84-0.98

Bladder

0.98 (0.01)

0.96-0.99

Left Femoral Head

0.97 (0.01)

0.96-0.99

Right Femoral Head

0.97 (0.01)

0.95-0.99

Penile Bulb

0.89 (0.10)

0.53-0.98

Rectum

0.94 (0.04)

0.80-0.98

DSC is the dice similarity coefficient
SD is the standard deviation

5.3.2 Time Analyses

The result of the time analysis is reported in Table 5.10. It compared the time spent
editing the automated contours to the manual contouring time. The mean (SD) time spent editing
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the automated contours and to manually contour all five patients was 14.1 minutes (8.4 minutes)
and 17.5 minutes (5.4 minutes), respectively, equating to a 24% time reduction when compared
to the manual contouring time. A paired t-test comparing the editing times of the automated
contours to the manual contouring times showed a significant difference in contouring times (p
value = 0.003). Figure 5.3 displays the results of the time comparison.

Table 5.10

Paired t-test analysis of the automated contouring workflow and the manual
contouring process

Time Analysis Comparison

Mean (SD) Time (minutes)

Time spent editing the automated contouring time

14.1 (8.4)

Manual contouring time

17.5 (5.4)

P value
0.003

SD is the standard deviation.

Figure 5.3

Time comparison between the editing time of auto-contours to the manual
contouring time
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6.0

Discussion

One of the most pressing issues in radiotherapy for cancer patients is the inter-observer
variability when contouring the clinical target volume (CTV) and regions of interest (ROI). The
lack of an easily definable gold standard and the ability to accurately and consistently delineate
the CTV and ROIs impacts the dose delivery to both the target and normal tissues, subsequently
affecting the potential for toxicity side effects. The present study reported on the validation of an
automated atlas-based segmentation (AABS) tool, the assessment of inter- and intra-observer
variability and the development of a methodology for the assessment of an AABS tool. The
AABS tool was validated for the delineation of the bilateral femoral heads, bladder and rectum,
while further improvements to the AABS tool will need to be made for the delineation of the
prostate bed and penile bulb. The inter-observer variability analysis indicates variability is
present in the delineation of the prostate bed and the bilateral femoral heads among experts, even
with the use of the RTOG consensus guidelines. Conversely, there appears to be little intra
observer variability. There was a significant reduction in contouring time when using the AABS
tool compared to manual contouring. Thus the use of the AABS tool may be reasonable for the
CTV and ROIs with appropriate review of contours.

6.1 Stage One: Construction of the Atlas

Though the total auto-contouring time appeared to slowly progress upwards, it was fairly
consistent throughout and the added seconds are not clinically relevant. The upward trend in time
is likely due to the increased amount of data to be analyzed prior to the selection of the most
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appropriate atlas subject by the AABS algorithm. The low correlation between the number of
subjects and the auto-contouring time suggest that as the number of subjects grow, the autocontouring time is not significantly affected. Ergo, further subjects can be added to the atlas
without a significant negative impact on the computational performance of the AABS tool. These
findings also provide further evidence that the performance of the atlas is dependent on the
deformable algorithm (Klein et al, 2009).
In CT imaging, the images are displayed on a gray-scale (on a Hounsfield scale) and the
differences in tissue density allow one to differentiate adjacent tissues. White represents tissues
(such as bones) with high Hounsfield units (HU), shades of gray have lower HU and often
represent soft tissues, fluid, fat and black spaces represent tissues (such as lungs and air-filled
organs) with the lowest HU. Hard tissues are defined as having high HU and soft tissues are
defined as having intermediary HU. The DSC results from Table 5.1 suggest the MIM atlas
generates automated contours with good overlap for the hard tissues, such as the bilateral
femoral heads. The automated contours for the hard tissues also demonstrate the least variability
among the other ROIs and the CTV. These results are consistent with the other results seen in
this study. Generally, the MIM atlas performed well in generating contours that are compliant
with the RTOG guidelines.
The atlas builder’s editing time for the CTV and ROIs all progressively decreased as
more subjects were added to the atlas. This evidence further supports the notion that the quality
of the automated segmentations improves with the number and quality of the segmentations in
the database. We can infer that as the quality of automated segmentations improve, the atlas
builder would conceivably spend less time editing the automated segmentations, and this was in
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fact seen in all the graphs in Appendix D. Alternatively, the results may also suggest the atlas
builder got faster at editing contours with practice.
The results from Table 5.2 suggest that the ability of the AABS tool to generate RTOG
compliant auto-contours for the bladder significantly improves when at least 45 patients are
added to the atlas, and again at 60 patients when compared to the first 15 patients in the atlas.
However, no further significant gains was seen when all 75 patients were added to the atlas for
the bladder. For the left femoral head, the results suggest each additional 15 patients added to the
atlas significantly improve the DSC when compared to the first set of 15 patients. For the right
femoral head, significant improvements in DSC was seen when at least 45 patients have been
added to the atlas and for every 15 patients that was subsequently added to the atlas (up to 75)
when compared to the first quintile. These results suggest that the MIM AABS tool must have at
least 45 patients to see significant improvements in DSC for the bladder and bilateral femoral
heads. However, the size of the atlas does not appear to affect the DSC for the prostate bed,
penile bulb and rectum. These results also describe the learning curve associated with the
algorithm. Therefore, to optimize the DSC and the number of atlas subjects for the bladder and
bilateral femoral heads, at least 45 patients are needed before the learning curve plateaus.

6.2 Stage Two: Assessment of the Automated Atlas-Based Segmentations and InterObserver Variability

The definition of the CTV (prostate bed) is a balance between encompassing the entire
area at risk of recurrence and minimizing the surrounding tissues exposure to radiation to reduce
toxicity effects. This continuum is difficult to navigate for many physicians and is the major
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reason for the existence of inter-observer variability. Figure 5.2 visually demonstrates the
variability among the observers in the delineation of the prostate bed. The inter-observer
variability seen in the prostate bed is consistent with other studies (Michalski et al, 2010;
Mitchell et al, 2009; Ost et al, 2011; Symon et al, 2011; Wiltshire et al, 2007). Mitchell and
colleagues (2009) assessed the inter-observer variability before and after the implementation of a
proposed delineation guideline (Wiltshire et al, 2007) and found considerable inter-observer
variability after the implementation of a delineation guideline. Ost et al (2011) evaluated inter
observer variability after the implementation of the European Organization for Research and
Treatment of Cancer delineation guidelines for the prostate bed (Poortmans et al, 2007) and
reported a kappa agreement = 0.49, suggesting that there was considerable variability. The
significant inter-observer variability findings seen in the bilateral femoral heads was unexpected,
but after examining the raw DSC data, it appears to be correct as a particular radiation oncologist
had a mean DSC of 0.49 for the left femoral head and 0.50 for the right femoral head, while all
other observers had DSC >0.80 for the bilateral femoral heads. That particular radiation
oncologist was confirmed to have systematically not conformed to the RTOG guidelines by
under-contouring the femoral shaft.
The results from the two-way ANOVA analyses determining the effects of the observer
and the patient on the DSC suggest that the observer had a significant effect on the DSC for the
prostate bed, bladder and the bilateral femoral heads. The patient had a significant effect on the
DSC for the prostate bed, bladder, penile bulb and rectum. For the prostate bed, the result
suggests it is a difficult region to contour manually and the anatomical differences among the
patients further complicate the task. Other studies have found similar results that illustrate the
difficulty in the contouring of the prostate bed, even among experts that have adopted a
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delineation guideline (Mitchell et al, 2009; Symon et al, 2011). The DSC for the bladder also
seems to be significantly affected by the observer and patient. But unlike the prostate bed, these
variables were able to explain the majority of the variation seen in the DSC for the bladder (88%
versus 29%). The variability in the DSC for the bilateral femoral heads appears to be the result of
the observers. Anatomical differences appear to have a minimal effect on the manual delineation
of the bilateral femoral heads. The opposite was true for the penile bulb and rectum. Anatomical
differences among patients significantly contributed to the variability that was seen in the DSC
for the penile bulb and rectum.
The two-way ANOVA analysis evaluating the effect of the observers and patients on the
manual contouring time suggests that both the observer and patient have significant effects on
the manual contouring time. These results are not surprising given the nature of the manual
contouring process.

6.3 Stage Three: Validation of the Automated Atlas-Based Segmentations

The MIM AABS tool was consistently able to contour hard tissues (bilateral femoral
heads) better than human observers and reduced the inter-observer variability for these
structures. In the generation of automated contours for soft tissues, the MIM AABS tool had
mixed results. Table 5.8 summarizes the comparison of the automated contours, the editedautomated contours and the manual contours by the expert panel to STAPLE. The literature
suggests a DSC > 0.70 represents good overlap (Zijdenbos et al, 1994). The edited-automated
contours for the left femoral head (DSC = 0.93), right femoral head (DSC = 0.92), bladder (DSC
= 0.88) and rectum (DSC = 0.78) had good spatial overlap, suggesting that editing the automated
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contours converges to the consensus contours. The auto-contours for the prostate bed fell just shy
of this threshold with a DSC = 0.67. The conceptual nature of the prostate bed requires a clinical
understanding of the empty space to be irradiated; making it difficult for the algorithm to
segment the conceptual space as the algorithm was developed to detect intact structures. To
quantitatively conclude the MIM AABS tool is superior or equivalent to human contouring, the
mean DSC must be higher or equivalent and the DSC variability must be lower or equivalent for
the CTV and ROIs when compared to the consensus contour. We are able to conclude that the
MIM AABS is superior to the manual contouring of hard tissues, but has mixed results for the
contouring of soft tissues and the prostatic fossa. That is, the MIM AABS tool appears to be
superior to human observers in the segmentation of high HU regions, but produce mixed results
for regions with intermediate to low HU.
The lower DSC seen in soft tissue delineation by the AABS may be in part due to the use
of CT images as CT images are limited in its ability to capture soft tissues. The use of magnetic
resonance imaging (MRI) technology could produce higher spatial overlap between the edited
auto-contours and the consensus contours. Recent studies have reported the advantages of using
MRI images for the segmentation of soft tissues such as the prostate due to the improved
capability in capturing soft tissues (Steenbakkers et al, 2003; Yeung et al, 2008).
We have shown that the atlas can be applied to different patients that are not part of the
atlas database. Regardless the different body shapes within different patients, the AABS tool can
be applied to these individuals to generate an AABS for treatment planning. The caveat, the
AABS must still be edited by the attending physician and this caveat is often repeated within the
literature (Reed et al, 2009; Stapleford et al, 2010; Teguh et al, 2010).
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The intra-observer variability results seen in the present study is consistent with other
findings (Wiltshire et al, 2007). These results suggest that the expert panel is consistent in their
contouring of the CTV and ROIs. Furthermore, inter-observer variability is the challenge that
future studies and AABS tools must address.
The time analysis demonstrated that the time spent editing the automated contours by the
radiation oncologists was significantly shorter than the typical manual contouring process. The
use of the AABS was shown to significantly improve the clinical efficiency in the delineation of
the CTV and the five ROIs. This was the first study to evaluate the potential of an AABS tool to
reduce the contouring time for prostate bed cases. Other studies have examined the autocontouring of an intact prostate gland and demonstrated a significant reduction in contouring
time (Lin et al, 2008; Pejavar, 2008). Significant reduction in contouring time was also found in
other studies, but these studies examined different anatomical regions (Teguh et al, 2010; Young
et al, 2011).

6.4 Development of the Technology Assessment Methodology

We developed a methodology to answer our specific questions and to give a
comprehensive perspective regarding the performance of an atlas-based segmentation tool and
the presence of inter- and intra-observer variability. Technology assessments of AABS often
encounter several inherent limitations that affect the evidential strength and interpretations of the
findings. The strength of our proposed methodology is that it outlines specific measures to
minimize the effect of these inherent limitations and to improve the evidential strength of the
findings by reducing bias. Most studies evaluate segmentation accuracy by comparing the auto
contours to manual segmentations by one or more experts. Due to the advancements in the
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literature, studies have started to adopt the use of a consensus-based estimate to compare the
auto-contours. The consistent findings that inter-observer variability exists among experts led to
the development of a consensus-based estimate for evaluation purposes (Warfield et al, 2004).
Therefore, the proposed methodology also adopts the use of a consensus-based estimate to
determine the accuracy of the auto-contours.
Inter-observer variability becomes another issue during the building of the atlas. Part of
the performance of the AABS tool is dependent on the manual segmentation by the atlas builder.
If the atlas builder segments the images similar to that of the expert panel, greater accuracy for
the auto-contours would be expected. Conversely, if the atlas builder segments the images
differently from the expert panel, the accuracy of the auto-contours would be negatively affected.
The use of the RTOG consensus guideline (Michalski et al, 2010) for the delineation of the
prostate bed was one measure to reduce inter-observer variability and to improve the accuracy of
the AABS tool. Other guidelines for the delineation of the prostate bed could have also been
used (Miralbell et al, 2007; Poortmans et al, 2007; Sidhom et al, 2008; Wiltshire et al, 2007).
Table 5.8 illustrates that the atlas builder had the highest spatial overlap and the lowest
variation in the contouring of the CTV and the five ROIs among the other STAPLE comparisons,
suggesting that the radiation oncologist that created the atlas was an appropriate individual to
construct the atlas. Our method quantitatively demonstrated the appropriateness of the atlas
builder to contour according to the RTOG guidelines and to a community of radiation
oncologists. To further limit inter-observer variability and to improve the performance of the
atlas, another radiation oncology professional audited the final atlas contours to ensure its
compliance to the consensus guidelines.
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Anonymizing the dataset and blinding the expert panel served several purposes. Firstly,
the anonymized dataset and blinding the expert panel was performed to objectively assess the
presence of intra-observer variability. Only 56% of the intra-observer contours were correctly
identified by the expert panel, suggesting that anonymizing the data and blinding the expert
panel served its purpose. Secondly, blinding the expert panel and subjecting them to anonymized
data provided insight on the choice of the consensus contour, STAPLE. All but one of the
STAPLE contours (96%) was deemed clinically acceptable, by far the highest percentage among
the manual contours and the auto-contours from the AABS. This provides further evidence
supporting the STAPLE technique for establishing consensus contours among multiple observers
to serve as gold or reference standards either for education or evaluation purposes. Thirdly, the
blinding of the dataset minimized any preconceptions the expert panel might have possessed had
they known the creator of the contoured CT image prior to editing.
Several metrics are available to researchers that can be applied to evaluate the accuracy
and consistency of automated segmentations. The Jaccard Similarity Coefficient (Jaccard, 1912),
mutual information (Zou et al, 2004), receiver operating characteristic analysis (Zou et al, 2004)
and distance-based statistics (Gerig et al, 2001) are other potential metrics. Researchers must
identify a specific question(s) to be answered as each of these metrics is best suited to answer
specific questions. Our proposed methodology uses the DSC because it has been validated for its
use in this regard (Zou et al, 2004). The DSC (Dice, 1945) is a simple spatial overlap index that
has been validated for its application in studies examining the accuracy and reliability in image
segmentations from manual or automated raters (Zou et al, 2004).
The contouring of the CTV and the surrounding normal tissues is a labor-intensive task
that can potentially be improved through the use of atlas-based segmentation tools. The time
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analysis in the current study is similar to that used in another study (Stapleford et al, 2010).
Stapleford and colleagues (2010) took a similar approach, and compared the time it took
physicians to edit the automated contours to the time it took to create manual contours for each
patient.
Based on the methodological choices, there are two caveats to the proposed methodology.
Our approach to estimating the performance of the AABS against the ground truth (within the
local dataset) to determine the accuracy of the AABS to the ground truth is a method often used
in the literature. However, since the ground truth (STAPLE) we used is an estimate, the
performance of the AABS is an estimate that utilizes the best available ground truth for
comparative purposes (Warfield et al, 2004). Secondly, those interested in using our atlas should
be aware that it was developed to comply with the RTOG guidelines for the delineation of the
prostate bed (Michalski et al, 2010). This caveat is important for any future research using this
particular atlas due to the fact that other guidelines differ in their recommendations for
contouring conventions, thus this may limit the generalizability of the atlas.

6.5 Limitations

Obtaining a sample of 80 patient DICOM datasets through consecutive sampling from the
LRCP Quality Assurance Imaging database to build and to test the atlas may limit the
applicability of the atlas to other geographical regions (that is, other cancer centers). Had we
used 5 datasets from a different geographical region to test the atlas, it may have provided a
stronger conclusion about the AABS tool’s performance on a new patient population. The
likelihood of anatomical differences in patients from another geographical region is likely low,
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but should be kept in mind when interpreting our results. We were able to test the AABS tool on
5 new DICOM datasets not part of the atlas, albeit from the same geographical area. As such,
future assessments of the AABS using a sample from a different geographical region
(particularly from different groups of radiation oncologists in different centers) may provide
greater insight.
Incorporating all available patients into the atlas building process has two important
drawbacks. While increasing the number of patients added to the atlas increases the potential to
account for shape variances in anatomical regions, one does it at the cost of some computational
time. The larger the atlas, the longer it will take the tool to search through the atlas to select the
best match. A slight increase in computational time was noted, but it was not clinically relevant.
Secondly, the anatomical shape variances may not necessarily be similar to that of the population
from which the CTV and ROIs are drawn. For this reason, a sample of 75 patients was used to
create the atlas in an attempt to include a plethora of structural shapes. One study used 10
patients (Teguh et al, 2010) and another study that assessed the same AABS tool included 15
patients in their atlas (Young et al, 2011).

6.6 Overall Study Interpretations

The present study reports on the development and results of a proposed technology
assessment methodology to validate an AABS tool, to assess inter- and intra-observer variability
in the delineation of the CTV (prostate bed) and the five ROIs (bilateral femoral heads, bladder,
rectum and penile bulb). We also report on the development of a RTOG compliant atlas for the
delineation of the prostate bed that can be applied to future studies. We found that manual

88

contouring of the CTV (the prostate bed) and the penile bulb should continue to be manually
contoured until the AABS tool has been improved and reassessed. The MIM AABS tool can be
used to generate AABS for the bilateral femoral heads, the bladder and the rectum with superior
to good spatial overlap compared to manual segmentations. The MIM AABS tool has been
validated for the bilateral femoral heads, bladder and rectum, but requires improvement for the
prostate bed and penile bulb. Clinical use of the atlas requires physicians to review and edit the
auto-contours prior to its use. The created atlas can be applied to clinics or future works, given
that the physicians and researchers understand the atlas generates auto-contours according to the
RTOG consensus guidelines for the delineation of the prostate bed.
We found that the time spent editing the auto-contours was significantly shorter than the
manual contouring time, equating to a 24% reduction in the contouring time. For this study, we
found that the AABS tool significantly reduces the contouring time for radiation oncologists.
Further, despite the adoption of the consensus guidelines, inter-observer variability in the
delineation of the CTV and the ROIs is present and intra-observer variability appears to be
minimal among a group of experienced radiation oncologists from a regional cancer centre in
Canada that treats a high volume of prostate cancer patients. Future research should focus on
reducing inter-observer variability through the use of AABS tools.
We proposed a general methodological approach to assess the accuracy and performance
of an AABS tool. Within the proposed methodology are steps to systematically assess inter- and
intra-observer variability. We attempted to address the limitations common to the assessment of
AABS tools and the creation of an atlas through the use of consensus guidelines, an appraisal of
the atlas from an objective rater, anonymized datasets, the blinding of the expert panel and the
circulation of a strategic dataset to the expert panel.
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We recommend that the MIM AABS tool can be adopted for routine clinical use to
generate auto-contours for the bilateral femoral heads, bladder and rectum. The caveat,
physicians will have to review and edit the automated contours for these regions. We have shown
that the AABS tool increases the accuracy and reduces the variability in the delineation of the
bilateral femoral heads (hard tissue), but it the tool had mixed results in the contouring of soft
tissues. Good spatial overlap was seen in the bladder and rectum regions in the comparison
between the edited-automated contours and the consensus contours. For the other soft tissue
regions, the AABS tool must improve its contouring of the prostate bed and the penile bulb. We
recommend that manual contouring continue for the prostate bed and penile bulb. However if the
MIM AABS tool was to be adopted for routine clinical use to contour the prostate bed and penile
bulb, the physicians must be meticulous in the editing of the automated contours to ensure the
entire CTV is covered while also minimizing the toxicity to normal tissues. Advancements to the
tool are recommended to improve the delineation of the soft tissues.
For those interested in assessing the accuracy and reliability of atlas-based segmentations,
we recommend researchers identify specific study objectives to determine a number of key
methodological measures. Researchers are recommended to investigate the existence of
published guidelines for the CTV of interest. Based on the study objectives and the researcher’s
preference, an appropriate measurement metric and reference estimation (contour) should be
selected. The versatility of the proposed methodology allows the researcher to modify the
metrics to fit study objectives and preferences. The undertaking of this study successfully yielded
a methodology to clinically evaluate and validate an AABS tool and to measure inter- and intra
observer variability.
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6.7 Directions for Future Research

Several future research directions can be pursued through the development and
completion of the current study. The emergence and the increasing popularity in AABS tools for
clinical use underscore the importance in evaluating AABS prior to its implementation into the
clinic. The developed methodology can be applied to future AABS evaluation studies to
determine the AABS’ ability to reduce inter- and intra-observer variability and contouring time
on the CTV of interest. Ideally, a clinical guideline for the delineation of the CTV of interest
should be consulted during the creation of the atlas to further reduce the contouring variability.
Second, the potential for MRI images to improve the soft tissue contrasts provide grounds
to repeat this study with a deformable registration of MRI images. One may hypothesize that the
deformable registration of MRI images to CT images would improve the inter-observer
variability and automated contouring of the CTV and the five ROIs.

6.8 Conclusion

In this study, we were the first group to report on the development and the results of a
proposed general methodology to assess the accuracy, reliability and potential time savings of an
automated atlas-based segmentation tool and to measure inter- and intra-observer variability in
the delineation of the prostate bed, bladder, bilateral femoral heads, penile bulb and rectum for
postoperative conformal radiotherapy in post-prostatectomy prostate cancer patients. We
demonstrated the capabilities of the automated atlas-based segmentation (AABS) tool to generate
auto-contours for the prostate bed, bladder, bilateral femoral heads, penile bulb, and rectum. The
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proposed methodology highlights the strengths and areas of improvement for the automated
atlas-based segmentations and systematically assesses the presence and amount of inter- and
intra-observer variability. As the field of atlas-based segmentations advances, it becomes
increasingly important to evaluate the accuracy and reliability of the atlas-based segmentations to
garner empirical evidence to support the decision-making process prior to its adoption for routine
clinical use.
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Appendix B: Stage two data collection sheet
There are 5 unique post-op prostate plans that need to be contoured
o Server: Clinical
O Institution: L R C P

R e s e a r c h P r o s ta te B e d

o Please contour the patients in the order in which they appear on the table provided
o Each patient has a plan specific to each physician (Specified by initials.) Please do
not open another physician’s treatment plan
o

On the provided table:
o Indicate the start time and completion time for each case.

o

In the C o n to u r s tab (locate at the top of the screen), the ROI labels have already
been created. Use these when contouring
o Prostate Bed
o Bladder
o Rectum
o Bilateral Femora (to level of ischial tuberosity)
o Penile Bulb

P A T IE N T

1
2
3
4
5

S t a r t T im e

E n d T im e

T o ta l T im e

Appendix C: Stage three data collection sheet
RTOG Prostate Bed Contouring phase III
Name:
INSTITUTION : RESEARCH PROSTATE BED
Open the data file as listed below. Be sure to open the case with your initials, save the file once you are done.
The contours are either your own, another Rad ones or generated via STAPLE or MIMVISTA.
Patient

1
2
3
4
1
2
3
4
1
2
3
4
4
1
2
3
4
1
2
3
4

End
Time

Contours
Acceptable?
(Y/N)

Whose contours do vou think they are?
(circle one)
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine
Mine

Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc
Other RadOnc

STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE
STAPLE

MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA
MIMVISTA

Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know

Ill

1
1
1
1
2
2
2
2
3
3
3
3
3
4
4
4
4
5
5
5
5

Start
Time

112

600

Prostate Bed

500

Editing Time (seconds)

Editing Time (seconds)

Editing Time (seconds)

Appendix D: Graphs depicting the time spent by the atlas builder to edit the auto-contours
of the CTV and the five ROIs
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Appendix D: Graphs depicting the time spent by the atlas builder to edit the auto-contours
of the CTV and the five ROIs continued...
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